US20010025643A1 - Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart - Google Patents

Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart Download PDF

Info

Publication number
US20010025643A1
US20010025643A1 US09/833,921 US83392101A US2001025643A1 US 20010025643 A1 US20010025643 A1 US 20010025643A1 US 83392101 A US83392101 A US 83392101A US 2001025643 A1 US2001025643 A1 US 2001025643A1
Authority
US
United States
Prior art keywords
conduit
blood
myocardium
heart
channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/833,921
Inventor
Mark Foley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Ventrica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventrica Inc filed Critical Ventrica Inc
Priority to US09/833,921 priority Critical patent/US20010025643A1/en
Publication of US20010025643A1 publication Critical patent/US20010025643A1/en
Assigned to MEDTRONIC, INC. reassignment MEDTRONIC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VENTRICA, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/94Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2493Transmyocardial revascularisation [TMR] devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • A61B2017/00247Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • A61B2017/00247Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • A61B2017/00252Making holes in the wall of the heart, e.g. laser Myocardial revascularization for by-pass connections, i.e. connections from heart chamber to blood vessel or from blood vessel to blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345Vascular system
    • A61B2018/00351Heart
    • A61B2018/00392Transmyocardial revascularisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/009Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof magnetic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008Fixation appliances for connecting prostheses to the body
    • A61F2220/0016Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028Shapes in the form of latin or greek characters
    • A61F2230/005Rosette-shaped, e.g. star-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063Three-dimensional shapes
    • A61F2230/0091Three-dimensional shapes helically-coiled or spirally-coiled, i.e. having a 2-D spiral cross-section
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0004Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof adjustable
    • A61F2250/0007Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof adjustable for adjusting length

Definitions

  • This invention relates to methods and devices providing transmyocardial blood flow or coronary revascularization for the treatment of coronary atherosclerosis and resulting myocardial ischemia.
  • the invention increases the flow of blood from one or more oxygenated blood sources within the patient to one or more sites selected in the arterial vascular system of the heart using a channel for maintaining and regulating blood flow therebetween. More particularly, a valve is inserted into a channel created and maintained between, or a valved conduit is inserted between, the left ventricle reservoir of oxygenated blood and the coronary artery distal to an area of obstruction.
  • Heart disease is a major medical ailment wherein arteries become narrowed or blocked with a build-up of atherosclerotic plaque or clot which reduces flow to tissues downstream or “distal” to the blockage. When this flow reduction becomes significant, a patient's quality of life may be significantly reduced. In fact, heart disease patients often die when coronary arteries become significantly blocked.
  • CABG coronary artery bypass graft
  • PTCA percutaneous transluminal coronary angioplasty
  • CABG surgery affixes a bypass graft between a port or aperture in a coronary artery wall distal to the blockage and a pressurized arterial blood supply, such as the aorta, to provide a conduit for blood flow into the coronary artery to the ischemic areas of the heart.
  • CABG surgery is generally initiated by directly exposing the heart to the surgeon by opening the patient's chest using known sternotomy and retraction techniques that cut the sternum and spread the rib cage open. Once the heart is exposed, the patient is connected to a cardiopulmonary bypass (“CPB”) machine so that the blood supply circumvents the heart.
  • CPB cardiopulmonary bypass
  • the heart is depressurized so that apertures can be cut into the walls of the vessels for surgical graft attachment.
  • the right atrium (or vena cava) and the aorta each is intubated with cannulas which are connected to an artificial pump and oxygenator. Once these major vessels are cannulated, the aorta is then clamped proximally of the aortic bypass cannula, thereby isolating the aortic root and heart from the blood that is being circulated by the CPB. Cardioplegia is then delivered to stop the beating motion of the heart.
  • the bypass grafting is achieved between the aorta and one of the three major coronary arteries or their sub-branches, the left anterior descending artery (LAD), the circumflex artery (CIRC), or the right coronary artery (RCA).
  • LAD left anterior descending artery
  • CIRC circumflex artery
  • RCA right coronary artery
  • a saphenous vein is usually taken from the patient's leg and is transplanted as a “homograft” to connect these vessels in order to provide blood flow to the compromised area of the coronary circulation.
  • Artificial grafts have also been disclosed as providing potential utility for this purpose.
  • An alternative CABG method uses the internal mammary artery (IMA) alone or in conjunction with the saphenous vein graft.
  • IMA internal mammary artery
  • the IMA is severed at a chosen location and is then connected to an aperture, in a coronary artery.
  • the fluid connections between a graft and a vessel are commonly referred to as “anastomoses.” Once the anastomosis of the bypass graft is complete, the heart is resuscitated and the patient is removed from CPB.
  • CABG surgery grafts have good long patency rates of about 60% to 90% over a ten year period, the isolation of the heart with the CPB and aortic cross-clamp carries a significant risk of mortality. It is believed that three critical determinants which affect outcomes of CABG surgery are: (1) time the patient spends on bypass, (2) time the patient spends with a clamped aorta, and (3) the quality of the anastomoses. It is generally believed that a CABG patient's operative and peri-operative morbidity are directly related to how long the patient must be on CPB. During prolonged periods on CPB, there is a greater chance for air and platelet embolization resulting from the artificial circuit.
  • such debris can embolize into the neurovasculature and potentially cause a stroke.
  • the time spent anastomosing the grafts to vessels emerges as a controlling factor.
  • a second CABG success factor related to the extent and time of aortic cross-clamping. It is believed that the inherent crushing force from a cross-clamp across the bridge of the muscular aortic arch may be associated with a high degree of tissue trauma and structural damage. Additionally, blood clots formed at or adjacent to the cross clamp, perhaps in conjunction with the tissue trauma of clamping, may also be a source of unwanted complications. In addition to the potential clinical complications associated with CABG surgery is also the cost of the time-consuming procedure.
  • a small incision is made in the patient's thigh to introduce a catheter into the femoral artery.
  • the catheter is guided to the internal blockage site via x-ray visualization.
  • the blockage is then treated remotely by use of hydraulic pressure in the case of balloon angioplasty wherein a balloon is inflated within the narrowed vessel to stretch or otherwise deform the blockage into a larger lumen.
  • other actuating means can be used to cause remote cutting or ablation of the blockage.
  • a stent is used to scaffold open the blocked area of the artery.
  • U.S. Pat. No. 5,655,548 by Nelson et al. discloses open surgical and transluminal methods for supplying long-term retrograde perfusion of the myocardium via a conduit disposed between the left ventricle and the coronary sinus. Blood ejected from the left ventricle enters the coronary sinus during cardiac systole. The outlet from the left ventricle to the coronary sinus may include a one-way valve to prevent backflow from the coronary sinus into the left ventricle during cardiac diastole.
  • the long-term artero-venous fistula that is created has the potential for edema or other physiologic effects.
  • the expandable stent can extend through the myocardium between the left ventricle and the coronary artery, but is completely within the myocardium and not extending into either the left ventricle or coronary artery.
  • the purpose of the expandable stent is to establish blood flow to the myocardium, and in some instances, to the coronary artery.
  • One design of the expandable stent is to collapse and close during systole.
  • the expandable stent can resist the contractive pressure of the heart to remain open during systole to permit the flow of blood through the stent into the myocardium and coronary artery.
  • the blood pumped into the coronary artery through the expandable stent can be blocked from returning to the left ventricle by an integrated, one-way valve.
  • the stent must be expandable and any valve therein must be integral with the stent.
  • the expandable stent is also sized to be only within, and not beyond, the myocardium.
  • the expandable stent fails to accommodate changes in the thickness of the myocardium wall during the rhythmic contraction of the heart which, according to Feigenbaum's textbook of Echocardiography, changes from an average thickness of about 8 mm in diastole to about 13 mm in systole.
  • the transluminal approach disclosed by Wilk can also have difficulty in delivering the expandable stent across coronary arteries which are substantially occluded. Approximately 60% of CABG surgery procedures are performed on totally occluded vessels where percutaneous access would not be feasible.
  • TMR transmyocardial revascularization
  • the present invention provides a method for increasing the flow of blood to a selected site in a patient's arterial vascular system of the heart.
  • the method includes the steps of: creating a channel for blood flow from an oxygenated blood source to the selected site in the arterial vascular system of the heart; maintaining the channel in an open position for blood flow through diastolic and systolic cycles of the heart; and regulating the blood flow in the channel to minimize blood flow from the coronary vascular system to the blood source during diastolic cycle of the heart.
  • the present invention also provides a method for performing a transmyocardial coronary revascularization procedure for the treatment of coronary atherosclerosis caused by an obstruction in the arterial vascular system.
  • the method includes the steps of: creating a channel for blood flow from an oxygenated blood source to the arterial vascular system distal to the area of obstruction; maintaining the channel in an open position for blood flow through the diastole and systole cycles of the heart; and regulating the blood flow in the channel to minimize blood flow from the arterial vascular system to the blood source during the diastolic cycle of the heart.
  • a method for treating an obstruction in a patient's cardiovascular system using a non-expandable conduit made of biocompatible material is also provided by the present invention.
  • the method includes the steps of: inserting the conduit completely through the myocardium of the patient's heart with one end of the conduit extending into the left ventricle and the other end of the conduit extending into the arterial vascular system distal to the area of obstruction; maintaining the conduit in an open position for blood flow through the diastolic and systolic cycles of the heart; and regulating the blood flow in the channel to minimize blood flow from the arterial vascular system to the left ventricle during the diastolic cycle of the heart.
  • Another method provided by the present invention increases the flow of blood to a selected site in a patient's arterial vascular system.
  • the method includes the steps of: inserting one end of a conduit into the left ventricle; inserting the second end of the conduit into the arterial vascular system at the selected site; maintaining the conduit in an open position for blood flow through the diastolic and systolic cycles of the heart; and regulating the blood flow in the conduit to minimize blood flow from the arterial vascular system to the left ventricle during the systolic cycle of the heart.
  • the present invention also includes conduits for maintaining a channel between an oxygenated blood source and a site in the arterial vascular system of the heart selected for delivering an increase of blood flow thereto.
  • the conduit includes a tubular body having an inlet end and outlet end between the blood source and selected site, respectively.
  • the conduit includes means for regulating the flow of blood between the blood source and selected site.
  • the conduit can include means for retaining the conduit in the myocardium with the inlet end extending into the left ventricle.
  • the conduit includes means for adjusting the conduit to the change of thickness of the myocardium during the heart cycle.
  • the present invention also provides a self-maintained channel created between an oxygenated blood source and a site in the arterial vascular system of the heart selected for delivering an increase of blood flow thereto.
  • the self-maintained channel maintains an open position during at least a portion of the heart cycle.
  • the self-maintained channel includes an inlet end and outlet end between the blood source and selected site, respectively.
  • the self-maintained channel includes an integral means for regulating the flow of blood between the blood source and selected site.
  • the self-maintained channel includes a natural or synthetic valve positioned therein as the regulating means.
  • FIG. 1 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created from the left ventricle to a coronary artery in accordance -with the present invention
  • FIG. 2 is a side view of another embodiment of the needle assembly illustrated in FIG. 1 for creating and dilating an access port in the myocardium or other tissue layer in accordance with the present invention
  • FIG. 3 is a side view of a delivery assembly for inserting a conduit into the myocardium or other tissue layer in accordance with the present invention
  • FIG. 4 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery to the left ventricle in accordance with the present invention
  • FIG. 5 is an integrated assembly to perforate, dilate, and insert a conduit into a channel in the myocardium or other tissue layer in accordance with the present invention
  • FIG. 6 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery and the left ventricle in accordance with the present invention
  • FIG. 7 is another embodiment of an integrated assembly to perforate, dilate, and insert a conduit into a channel in the myocardium or other tissue layer in accordance with the present invention
  • FIG. 8 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery, both distal and proximal to a blockage, and to the left ventricle in accordance with the present invention
  • FIG. 9 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created along an extended portion of the myocardium from a coronary artery, both distal and proximal to a blockage, and to the left ventricle in accordance with the present invention
  • FIG. 10 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery to a coronary vein and into the left ventricle in accordance with the present invention
  • FIG. 11 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a surgical method into a channel created from a coronary vein into both a coronary artery and the left ventricle in accordance with the present invention
  • FIG. 12 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery, both distal and proximal to a blockage, through a coronary vein and into the left ventricle in accordance with the present invention
  • FIG. 13 is partial cross-sectional view of a conduit positioned within the myocardium in accordance with the present invention.
  • FIG. 14 is a schematic cross-sectional view of a human heart showing a conduit inserted by a percutaneous method into a channel created from the left ventricle to a coronary artery in accordance with the present invention
  • FIG. 15 is a schematic cross-sectional view of a human heart showing a conduit inserted by a percutaneous method into a channel created from a coronary artery to the left ventricle in accordance with the present invention
  • FIG. 16 is an integrated assembly to percutaneously perforate, dilate, and insert a conduit into a channel in the myocardium or other tissue layer in accordance with the present invention
  • FIG. 17 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a percutaneous method into a channel created from a coronary artery to a coronary vein and into the left ventricle in accordance with the present invention
  • FIG. 18 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a percutaneous method into a channel created from a coronary artery into a coronary vein distal to the channel into the left ventricle in accordance with the present invention
  • FIG. 19 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a percutaneous method into a channel created from a coronary artery, both distal and proximal to a blockage, through a coronary vein and into the left ventricle in accordance with the present invention
  • FIG. 20 is a cross sectional view of an embodiment of the valved conduit having projections as retaining means in accordance with the present invention.
  • FIG. 21 is a cross sectional view of another embodiment of the valved conduit having projections as retaining means in accordance with the present invention.
  • FIG. 22 is a cross sectional view of an embodiment of the valved conduit having a thread as retaining means in accordance with the present invention
  • FIG. 23 is a cross sectional view of an embodiment of the valved conduit having a flared end as retaining means in accordance with the present invention.
  • FIG. 24 is a cross sectional view of an embodiment of the valved conduit having a coating as retaining means in accordance with the present invention.
  • FIG. 25 is a cross sectional view of an embodiment of the valved conduit having slots as retaining means in accordance with the present invention.
  • FIGS. 26A and 26B are cross sectional views of the myocardium changing thickness along a conduit during systole and diastole, respectively, in accordance with the present invention
  • FIG. 27 is a cross sectional view of an embodiment of the valved conduit having telescoping sections as adjusting means in accordance with the present invention.
  • FIG. 28 is a cross sectional view of an embodiment of the valved conduit having telescoping sections as adjusting means in accordance with the present invention.
  • FIG. 29 is a cross sectional view of an embodiment of the valved conduit having an accordion section as adjusting means in accordance with the present invention.
  • FIG. 30 is a cross sectional view of an embodiment of the valved conduit having a lateral accordion section as adjusting means in accordance with the present invention
  • FIG. 31 is a cross sectional view of an embodiment of the valved conduit having a coil as adjusting means in accordance with the present invention.
  • FIG. 32 is a side view of an embodiment of the conduit having a branch configuration in accordance with the present invention.
  • FIG. 33 is a side view of an embodiment of the conduit having a hook configuration in accordance with the present invention.
  • FIG. 34 is a side view of an embodiment of the conduit having a hybrid synthetic/natural configuration in accordance with the present invention.
  • FIG. 35 is a cross sectional view of a vein used as a valve in accordance with the present invention.
  • FIG. 36 is a cross sectional view of another embodiment of a vein used as a valve in accordance with the present invention.
  • FIG. 37 is a cross sectional view of a valve in accordance with the present invention.
  • FIG. 38A and FIG. 38B are side views of a conduit regulating blood flow during two phases of the heart cycle in accordance with the present invention.
  • FIG. 39 is a cross sectional view of a valve in a self-maintained channel in the myocardium in accordance with the present invention.
  • FIG. 40 is an isolated front view of the valve in FIG. 39;
  • FIG. 41 is a cross sectional view of a self-maintained channel in the myocardium in accordance with the present invention.
  • FIG. 42 is a cross sectional view of a self-maintained channel in the myocardium in accordance with the present invention.
  • the present invention generally describes a transmyocardial approach wherein one or more new channels, which are preferably about the size of a coronary artery, are formed between the left ventricle or other oxygenated blood source and one or more sites in the arterial vascular system of the heart selected for increasing the flow of blood thereto.
  • the selected site is in a position distal to one or more obstructed areas within the coronary circulation.
  • the channel is created by penetrating completely through the tissue defining the blood source, such as the myocardium which defines the left ventricle, or the vascular tissue, which defines a coronary artery.
  • the channel is maintained in an open state, by mechanical means or through tissue removal, in order for blood to flow through during the cycle of the heart.
  • the channel is regulated or valved controlling both the direction and/or the quantity of blood flow through the channel between the left ventricle and the selected site in the arterial vascular system of the heart.
  • the present invention includes several methods for creating and maintaining a channel in the myocardium for the purposes of connecting an oxygenated blood source to the arterial vascular system of the heart, compromised by a coronary blockage.
  • the inventive methods include both surgical and percutaneous approaches.
  • the surgical approaches include direct access to the exterior of the patient's heart via a chest or thoracic approach.
  • the percutaneous approaches include a minimally invasive technique using catheters or other devices which are inserted into the patients' vessels or heart at a remote access site and guided to the internal blockage site via visualization by instrumentation. The revascularization is then accomplished remotely.
  • diastole refers to the normal rhythmical relaxation of the heart chamber, especially the ventricles, during which they fill with blood.
  • systole refers to the rhythmic contraction of the heart, especially the ventricles, during which blood is driven through the aorta and pulmonary artery after each diastolic period.
  • distal is generally defined as in the direction of the patient, or away from a user of a device, or in a downstream direction relative to a forward flow of blood. In the context of a medical device intervention with or through a vascular tissue layer, distal herein refers to the interior or the lumen side of the vascular tissue layer or wall.
  • proximal generally means away from the patient, or toward the user, or in an upstream direction relative to a forward flow of blood.
  • proximal herein refers to the exterior or outer side of the vascular tissue layer or wall.
  • arterial vascular system of the heart includes, but is not limited to, the myocardium and coronary arteries.
  • the present invention is specifically described below with regard to the coronary artery, it should be understood that the present invention is not so limited and that the description is applicable to any part of the arterial vascular system of the heart.
  • the description is applicable to the left anterior descending artery, the circumflex artery, the right coronary artery, and their tributaries.
  • the description is also specific with regard to the left ventricle, but is applicable to other oxygenated blood sources of the arterial vascular system such as the left anterior descending artery, the circumflex artery, the right coronary artery, and their tributaries proximal to any obstruction or blockage.
  • a preferred method of the present invention is a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary vascular system 10 through the chest area using a needle assembly 12 as illustrated in FIGS. 1 and 2. Similar components between the figures herein are denoted by the same reference numerals.
  • An initial access port 14 in the myocardium is made by advancing the needle assembly 12 through the myocardium 16 from the exterior side 18 of the myocardium 16 and into the left ventricle 20 . Then a second access port 22 in the myocardium is made from the interior side 24 of the myocardium within the left ventricle 20 and underneath the coronary artery 26 .
  • the needle assembly 12 is advanced through the myocardium 16 from the left ventricle 20 and into the coronary artery 26 at a point distal to the lesion or blockage 28 .
  • a guide wire 30 or other directional means is extended from the distal end 32 of the needle assembly into the coronary artery 26 .
  • a sufficient length of the guide wire 30 is advanced into the coronary artery 26 to prevent its premature withdrawal.
  • the distal end 34 of the guide wire can contain a balloon 36 or other temporary anchoring means to prevent premature withdrawal of the guide wire 30 from the coronary artery.
  • the proximal end 38 of the guide wire extends through the left ventricle 20 to the exterior 18 of the myocardium where it is available for manipulation by the surgeon.
  • the method uses the connection made by the second access port 22 between the left ventricle 20 and the coronary artery 26 to create and maintain a channel 42 therebetween.
  • the initial access port 14 is dilated to allow the advancement of a delivery device 44 as illustrated in FIG. 3 having a sheath 46 covering a valved conduit 48 .
  • the sheath 46 is configured to assist the passage of the valved conduit 48 through the initial access port 14 without snagging the valved conduit 48 or damaging the myocardium 16 .
  • the delivery device 44 is advanced over the guide wire 30 , through the initial access port 14 , and into the left ventricle 20 .
  • the guide wire 30 directs the delivery device 44 to the second access port 22 .
  • the valved conduit 48 is then removed from the sheath 46 with a pusher rod 74 and the delivery device 44 inserts the valved conduit 48 into the second access port 22 so that the valved conduit 48 extends through the myocardium 16 from the left ventricle 20 to the coronary artery 26 .
  • the conduit 48 keeps the second access port 22 dilated and maintains the channel 42 between the left ventricle 20 and the coronary artery 26 .
  • the end 50 of the conduit preferably extends into the left ventricle 20 during the rhythmic contractions of the heart. It is preferred that the valved conduit end 50 extends into the left ventricle 20 at least during diastole when the myocardium is at the minimal thickness of its cycle.
  • the other end 52 of the conduit can be approximately flush with the exterior 18 of the myocardium or extends slightly into the coronary artery 26 during at least during the diastole when the myocardium is at the minimal thickness of its cycle.
  • the remainder of the delivery device 44 is then withdrawn from the left ventricle 20 through the initial access port 14 .
  • the balloon 36 at the distal end 34 of the guide wire is deflated (or the temporary anchor means is retracted) allowing withdrawal of the guide wire 30 from the coronary artery 26 along the valved conduit 48 and from the left ventricle 20 through the initial access port 14 .
  • the initial access port 14 is then sealed with a suture or allowed to seal itself without assistance.
  • another embodiment of the present invention effectively anchors the distal end 34 guide wire by initially continuing to advance the guide wire beyond the coronary artery 26 .
  • the distal end 34 A of the guide wire is advanced through the interior 70 and exiting from the exterior side 72 of the coronary artery. The distal end 34 A is then exposed for anchoring in position.
  • the needle assembly 12 can be of any shape sufficient to perforate and penetrate the myocardium 16 while minimizing tissue damage.
  • FIG. 1 shows the needle assembly 12 having a curved shape which can assist in initially penetrating from the exterior side 18 of the myocardium and continuing to penetrate the interior side 24 of the myocardium underneath the coronary artery 26 .
  • Other shapes for the needle assembly 12 are suitable for use in the present invention which can penetrate and can depend upon the particular surgical approach to be used.
  • FIG. 2 illustrates a straight needle assembly 12 , commonly referred to as a seldinger-type needle.
  • a suitable diameter for the needle component 40 is about 12 gauge.
  • FIG. 2 specifically illustrates more details of the needle assembly 12 other than an alternate shape.
  • the needle assembly 12 includes a needle component 40 having at least one lumen 54 extending substantially across length of the needle component.
  • the first lumen 54 can be used to allow blood flow therethrough.
  • the blood in the left ventricle 20 will travel through the lumen 54 and blood 66 will be visually observed exiting the proximal end 62 of the needle assembly. This bleeding “flashback” 66 is especially prominent during the contraction of the left ventricle 20 .
  • the first lumen 54 is also used to retractably carry the guide wire 30 therethrough.
  • the assembly 12 can include a second lumen 56 which also extends substantially across the length of the needle component 40 .
  • One end 58 A of the second lumen is located at the distal end 32 of the needle component.
  • the end 58 B of the second lumen is located at some predetermined distance from the distal end 32 of the needle component.
  • the other end 60 of the lumen is located near the proximal end 62 of the needle component.
  • the blood in the left ventricle 20 will travel from one end 58 A or 58 B of the second lumen to the other end 60 and blood 66 will be visually observed exiting the proximal end 62 of the needle assembly.
  • the lumen 54 or second lumen 56 and its ends 60 and 58 A or 58 B act as marker ports which provide evidence when the distal end 32 of the needle assembly is first in the left ventricle 20 and subsequently in the coronary artery 26 .
  • Other means for marking the position of the distal end 32 of the needle assembly are suitable for use with the present invention.
  • the depth of the penetration through the myocardium to form the initial and second access ports 14 and 22 can be estimated by conventional diagnostic imaging and/or by reading one or more depth markers 68 placed in predetermined positions along the length of the needle assembly 12 .
  • the needle assembly 12 provides for perforating the myocardium 16 to create and access port.
  • the assembly 12 also provides for dilating the access port and for ensuring the position of the assembly has been advanced into the left ventricle 20 and/or coronary artery 26 .
  • Another inventive method is a surgical approach which gains access to the exterior of the patient's heart illustrated in FIG. 4 through conventional cardiac surgical methods.
  • an initial access port 76 is made in the coronary artery 26 distal to the point of the obstruction 28 .
  • the needle assembly 12 is advanced into and through the coronary artery 26 to contact the exterior 18 of the myocardium underneath the coronary artery 26 .
  • the needle assembly 12 is further advanced to penetrate the myocardium 16 and make an access port 78 in the myocardium while eventually entering the left ventricle 20 .
  • the needle assembly 14 extends into the left ventricle 20 to the extent that flashback bleeding 66 is observed to assure the myocardium 16 has been completely penetrated.
  • a guide wire 30 or other directional means is extended from the distal end 32 of the needle assembly into the left ventricle 20 .
  • a sufficient length of the guide wire 30 is advanced into the left ventricle 20 to prevent its premature withdrawal.
  • the distal end 34 of the guide wire can contain an inflatable balloon 36 or other temporary anchoring means to prevent premature withdrawal of the guide wire 30 from the left ventricle 20 .
  • the initial access port 76 is created in the exterior of the coronary artery 26 , it may be desirable to offset the alignment of the initial access port shown as 76 A from the myocardium access port 78 .
  • This can be accomplished in several ways such as through simple angling of the needle assembly 12 while creating the access ports or using a needle assembly 12 which is curved or has an offset in its configuration.
  • the eventual closing of the initial access port 76 may cause trauma to the vascular tissue in that area.
  • Providing an offset in the alignment of the access ports 76 A, 78 avoids the initial access port area from being directly over or along the path of the blood flow path from the inserted valved conduit 48 .
  • the access port 78 in the myocardium is dilated to accommodate the delivery of a valved conduit 48 therein. Inserting the valved conduit 48 into the access port 78 creates and maintains by mechanical means a channel 42 through the myocardium from the left ventricle 20 to the coronary artery 26 .
  • the delivery of the valved conduit 48 can be effectuated by inserting a guide wire 30 , withdrawing the needle assembly 12 , directing a delivery assembly 44 as seen in FIG.
  • An alternate embodiment of the present invention employs a needle assembly and delivery assembly which are integrated so that the guide wire is eliminated.
  • the integrated assembly provides sufficient dilation of the respective access ports to deliver the valved conduit therein.
  • an integrated assembly 80 includes a perforating distal end 82 with a series of gradations or steps 84 for gradually dilating the respective access port as the integrated assembly 80 is further advanced.
  • the steps 84 can be pre-formed or result from a retractable telescoping of the body 86 of the integrated assembly which can gradually vary its diameter.
  • valved conduit 48 is then removed from the body 86 with a pusher rod 88 and the integrated assembly 80 inserts the valved conduit 48 into the access port 78 so that the valved conduit 48 extends through the myocardium 16 from the left ventricle 20 to the coronary artery 26 .
  • the conduit 48 keeps the access port 78 dilated and maintains the channel 42 between the left ventricle 20 and the coronary artery 26 .
  • Still another inventive method is a surgical approach which gains access to the exterior of the patient's heart and coronary vascular system 10 illustrated in FIG. 6 through conventional cardiac surgical methods.
  • an access port 92 is created through the myocardium 16 from the exterior side 18 into the left ventricle 20 .
  • the distal end 98 of the integrated needle assembly perforates the myocardium and the myocardium access port 92 is dilated to accommodate the delivery of one end 96 of the valved conduit 94 which is advanced into the myocardium access port 92 . Inserting the end 96 of the valved conduit into the myocardium access port 92 creates and maintains a channel through the myocardium 16 from the left ventricle 20 into one end 96 of the valved conduit.
  • an artery access port 102 is made in the exterior side 72 of the coronary artery.
  • the second integrated needle/assembly 100 can immediately dilate the artery access port 102 and insert the other end 104 of the valved conduit after the integrated needle/delivery 100 perforates the coronary artery 26 . Inserting the other end 104 of the valved conduit into the artery access port 102 creates and maintains a channel 42 from the left ventricle 20 into one end 96 of the valved conduit, out the other end 104 of the valved conduit, and into the coronary artery 26 .
  • the first needle/delivery assembly 90 is more specifically illustrated in FIG. 7 which includes a body 106 made of a flexible material.
  • the body 106 is perforated along its longitudinal axis to form seams 108 .
  • the valved conduit 94 extends along the longitudinal axis of the body 106 with the end 96 of the valved conduit positioned near the distal end 98 of the assembly and the other end 104 of the valved conduit exiting from the proximal end 110 of the assembly.
  • the assembly 90 has perforated and dilated the myocardium access port 92 , gripping the other end 104 of the valved conduit exiting from the assembly 90 can be helpful in either advancing the end 96 of the valved conduit into the myocardium access port 92 or holding the end 96 of the valved conduit within the myocardium access port 92 as the remainder of the assembly 90 is withdrawn.
  • the perforations are broken apart to split the seams 108 and the longitudinal sections 112 and 114 of the body 106 are peeled away leaving the end 96 of the valved conduit in the myocardium access port 92 .
  • the valved conduit 94 can have two separate conduit sections wherein a first conduit section 118 is inserted in the myocardium access port 92 and a second conduit section 119 is inserted in the artery access port 102 . Subsequently, the two sections are connected together to form a continuous channel for the blood flow from the left ventricle 20 to the coronary artery 26 .
  • the valve 116 can be integrally positioned in either the first or second conduit section. Or, the valve 116 can be a separate piece from the two conduit sections wherein each conduit section connects to opposite sides of the valve.
  • delivery of either end 96 or 104 , or both ends, of the valved conduit 94 can be effectuated by inserting a guide wire through a needle assembly as illustrated in FIG. 2 into the left ventricle 20 , withdrawing the needle assembly, directing a delivery assembly as illustrated in FIG. 3 containing the valved conduit 94 over the guide wire to the myocardium access port 92 , dilating the myocardium access port 92 , inserting one end 96 of the valved conduit into the myocardium access port 92 , and withdrawing the delivery assembly and guide wire from the left ventricle 20 .
  • a further inventive method is a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary vascular system illustrated in FIG. 8.
  • a myocardium access port 122 is made in the myocardium 16 from the exterior side 18 into the left ventricle 20 .
  • the myocardium access port 122 is dilated to accommodate the delivery of a first input end 124 of a Y-shaped, multi-branched valved conduit 126 therein. Inserting the first input end 124 of the valved conduit into the myocardium access port 122 creates and maintains a channel 148 through the myocardium 16 from the left ventricle 20 into a first input end 124 of the conduit.
  • a distal artery access port 130 is made in the exterior side 72 of the coronary artery at a point distal to the lesion or blockage 28 .
  • the second assembly 128 can immediately dilate the distal artery access port 130 and insert an output end 132 of the multi-branched conduit after the second assembly 128 perforates the coronary artery 26 .
  • a proximal artery access port 136 is made in the exterior side 72 of the coronary artery at a point proximal to the obstruction or blockage 28 .
  • the third assembly 134 can immediately dilate the proximal artery access port 136 and inserts a second input end 138 of the multi-branched conduit after the third assembly 134 perforates the coronary artery 26 .
  • Inserting the first input end 124 of the multi-branched conduit into the myocardium access port 122 and the second input end 138 of the multi-branched conduit into proximal artery access port 136 creates and maintains two channels 140 and 142 from two different blood sources, namely the left ventricle 20 and the coronary artery 26 proximal to the blockage 28 , into the output end 132 of the multi-branched conduit and into the coronary artery distal to the blockage 28 .
  • a multi-branch, valved conduit 126 is used having at least two branches 140 and 142 with valving means 144 located in branch 140 .
  • the two input ends 124 and 138 and output end 132 of the valved conduit each can be inserted similar to the previous description of FIGS. 6 and 7 without the assistance of remote guidance which avoids using a guide wire or the like through the interior of the conduit.
  • each branch 140 and 142 of the conduit can initially be a separate component which can be connected together after the two input ends and output end have been inserted into the myocardium and the coronary artery proximal and distal to the blockage.
  • the valving means 144 minimizing blood flow into the left ventricle is located in the branch 140 leading from the myocardium 16 between the first input end 124 and the connection to the second input end 138 and the output end 132 .
  • the valving means 144 can be located near the distal artery port 130 as shown in phantom as 148 .
  • a second valving means 146 for minimizing blood flow into the proximal coronary artery can be located in branch 142 leading from the proximal coronary artery between the second input end 138 and the connection between the first input end 124 and the output end 132 .
  • a second valving means 146 is particular useful if there is a valving means located near the distal artery port 130 .
  • FIG. 8 a portion of the surgical approach described in FIG. 8 can be used to connect the proximal and distal coronary artery 26 with a channel like branch 142 external to the heart.
  • a surgical approach as described in FIGS. 1 or 4 can provide an internal channel like 42 (FIGS. 1 or 4 ) positioned through the myocardium 20 .
  • FIGS. 1 or 4 blood flow from the left ventricle 20 arrives to the distal coronary 26 by an internal channel like 42 and from the proximal coronary artery through external channel like 142 .
  • FIG. 9 illustrates another embodiment of a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary vascular system 10 for the placement of a valved conduit 150 through an extended portion along, or at an obtuse angle through, the myocardium 16 rather than taking the shortest path roughly perpendicularly through the myocardium.
  • proximal artery access port 156 is made on the exterior side 72 of the coronary artery.
  • the assembly 154 is advanced through the interior 70 of the coronary artery and along the myocardium before eventually creating an access port 160 to the left ventricle 20 through the myocardium 16 .
  • the proximal artery access port 156 and left ventricle access port 160 are dilated to accommodate the delivery of one branch 162 of the valved conduit 150 so that the valved conduit 150 is positioned at least partially along the myocardium and is preferably subjected to the movement created by the rhythmic contractions of the beating heart.
  • a distal artery access port 168 is created through the coronary artery 26 at a point distal to the lesion or blockage 28 into the exterior side 18 of the myocardium to connect with or near the left ventricle access port 160 .
  • the second assembly 166 can immediately dilate the distal artery access port 168 and insert the other branch 164 of the valved conduit into the coronary artery 26 .
  • the valved conduit 150 has two branches 162 , 164 which traverse the myocardium 16 at an obtuse angle.
  • the valved conduit 150 exhibits a substantially greater length compared to perpendicularly traversing the myocardium between the left ventricle 20 and coronary artery 26 .
  • valved conduit 150 can have a solid, rigid design, it is preferred in this embodiment to advantageously use the movement created by the rhythmic contractions of the beating heart to provide the regulation of the blood flow from the left ventricle 20 to the coronary artery 26 distal to the blockage 28 . Accordingly, it is preferred that a substantial length the valved conduit 150 be made of a flexible material which allows the walls 152 of the valved conduit to flex with the rhythmic contractions of the beating heart and assist in the regulation of blood flow. The flexing of the conduit walls 152 can occur in several ways such as compression of its diameter or the lateral collapse of the conduit walls 152 upon themselves.
  • each branch 162 , 164 has a separate access port to the left ventricle 20 .
  • valve 158 it is suitable to remove the valve 158 as a distinct component of the conduit by allowing the conduit walls 152 to flex by collapsing opposing walls against each other to provide the appropriate degree of closure during diastole. It may also be desirable to provide for regulating blood through both branches by locating the valve 158 only in branch 162 . Examples of the proper alignment of the valved conduit 150 traversing the myocardium 16 are described in more detail below.
  • valved conduit 150 Other means of positioning the valved conduit 150 along a more extensive path between the left ventricle 20 and coronary artery 26 are suitable for use in the present invention.
  • the direct access to the exterior of the heart 10 allows a trough to be excised between the left ventricle access port 160 and the distal artery access port 168 .
  • the left ventricle access port 160 can be created at one end of the trough and the distal artery access port 168 at the other end of the trough.
  • One end of the valved conduit 150 is then positioned into the left ventricle and extends within the trough to the other end of the valved conduit which is inserted into coronary artery 26 as previously described therein.
  • valved conduit 150 is specifically illustrated as traversing the myocardium along an extended path or obtuse angle, it should be noted that the present invention is not so limited.
  • the valved conduit 150 can be positioned partially or wholly within the myocardium including other tissue layers enveloping the heart i.e. pericardium, epicardium, endocardium, etc., or external to the heart and vascular system, or in a combination thereof.
  • valved conduit 150 of FIG. 9 Another embodiment of the surgical approach using the valved conduit at least partially positioned within the myocardium is to utilize a valved conduit with only one branch similar to the methods illustrated in FIGS. 1, 4 and 6 .
  • other branches are added to the valved conduit 150 of FIG. 9 to connect to other sources of oxygenated blood, namely another coronary artery, or to deliver the oxygenated blood to multiple ischemic areas.
  • Each additional branch can be positioned across the myocardium along an extended path or obtuse angle as described above or in a perpendicular direction across the myocardium.
  • FIG. 10 illustrates another embodiment of a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary vascular system 10 for the placement of a valved conduit 180 across the myocardium 16 .
  • a needle/delivery assembly 182 creates an initial access port 184 in the exterior side 72 of the coronary artery distal to the blockage 28 .
  • the assembly 182 is advanced through the interior 70 of the coronary artery to create an access port 190 through the vascular wall 186 of an adjacent coronary vein 188 .
  • the assembly 182 is then advanced through the coronary vein 188 to create an access port 192 in the exterior side 18 of the myocardium and completely through the myocardium 16 into the left ventricle 20 .
  • the valved conduit 180 is then inserted into and through the myocardium 16 creating a channel 42 directly from the left ventricle 20 to the coronary vein 188 .
  • the blood flow into the coronary vein 188 is limited to a particular area or section 170 by inserting plugs 194 within the coronary vein proximal and distal to the access ports 190 , 192 .
  • the plugs 194 can be moved into their respective positions by insertion through the access ports 184 , 190 .
  • Another technique for inserting the plugs 194 is to perforate, dilate, and insert the plugs 194 directly through the exterior side of the coronary vein 188 near the area the plugs 194 are desired.
  • Devices or techniques other than plugs 194 can be used to isolate a section of the coronary vein 188 such as by using a suture around the vein in a position at least proximal to the access ports 190 , 192 to close off blood flow to the section.
  • a second conduit 196 is inserted into the access port 190 to maintain a second channel 198 between the coronary artery 26 and the coronary vein 188 .
  • blood flows during systole from the left ventricle 20 into the coronary vein 188 and subsequently into the coronary artery 26 distal to the blockage 28 .
  • the coronary vein 188 can provide a temporary reservoir of blood.
  • the valved conduit 180 minimizes backflow of blood from the coronary vein and artery during diastole.
  • the conduit 180 can optionally include a reservoir connected to it for temporarily storing blood.
  • the reservoir may be a separate container like the section 170 of the coronary vein 188 that is connected to the conduit 180 or a container that is integrally formed with the surface of the conduit.
  • the reservoir can also be effectively formed from a material which has the ability to expand and contract so that it becomes a reservoir during certain periods of the heart cycle.
  • the assembly 182 can be elongated to initially contain both the valved conduit 180 and the second conduit 196 so that each may be respectively positioned without withdrawing the needle assembly from the initial access port 184 .
  • Other alternates are available, such as withdrawing the needle assembly 182 to reload with the conduit not first placed in position. Or, temporarily dilating the access port 184 with another device so that a second needle/delivery assembly can be inserted through the same access port.
  • valved conduit 180 Although there is only one valved conduit 180 and it is positioned completely through the myocardium 16 , the present invention includes several other options for regulating blood flow. For example, one option is to position the valved conduit 180 between the coronary artery 26 and coronary vein 188 and position the second conduit 196 without a valve through the myocardium between the left ventricle 20 and the coronary vein 188 . This arrangement creates a reservoir of blood within the coronary vein 188 which may allow for blood flow into the coronary artery 26 during diastole.
  • FIG. 10 Another option positions the valved conduit 180 and second conduit 196 as illustrated in FIG. 10. However, a valve shown in phantom as 180 A is added to the second conduit 196 . As a result, the coronary vein 188 provides a reservoir of blood in section 170 which augments blood flow into the coronary artery 26 during diastole.
  • Another embodiment of this surgical approach wherein the channel between the left ventricle and coronary artery is transvascular and transmyocardial as illustrated in FIG. 11.
  • An initial access port 184 A is created in the top exterior of the coronary vein 188 instead of the coronary artery 26 .
  • the assembly 182 is advanced to create the access port 190 into the coronary artery 26 , to insert the second conduit 196 and is then withdrawn.
  • the assembly is also advanced from the initial access port 184 A to create the access port 192 into the myocardium 16 , insert the valved conduit 180 and is then withdrawn.
  • the initial access port 184 A is created to advance the assembly 182 and create an access port from the coronary vein 188 to either the left ventricle 20 through the myocardium 16 or to the coronary artery 26 , but not both.
  • Another initial access port 184 B is created with the same or another assembly to complete the remaining access port.
  • access port 192 is made through the myocardium and the alternate access port 184 B is used to make alternative access port 190 B into the coronary artery 26 .
  • the alignment of the access ports 190 B, 192 is offset from one another.
  • valved conduit 180 is specifically illustrated in FIGS. 10 and 11, the coronary vein 188 itself can be used to regulate the flow of blood from the left ventricle 20 into the coronary artery 26 .
  • the conduits 180 and 196 need not be valved, but simply maintain the respective channels.
  • the natural valving function of vascular tissue in the isolated section of the coronary vein 188 can be advantageously used to regulate the flow of blood.
  • the present invention includes still another surgical approach wherein transvascular and transmyocardial channels between the left ventricle and coronary artery extend to more than one blood source as illustrated in FIG. 12.
  • An additional initial access port 174 A is created in the top exterior of the coronary vein 188 at a position which is proximal to the blockage 28 in the adjacent coronary artery 26 .
  • the assembly 182 is advanced through the interior of the coronary vein 188 to create an additional access port 172 for a third channel 178 through the exterior wall 72 of an adjacent coronary artery.
  • a third conduit 176 is inserted into the additional second access port 172 to maintain the channel 178 .
  • One of the plugs 194 is inserted into the coronary vein 188 in a proximal position to the additional initial access port 174 A.
  • the additional initial access port 174 B is created in the top exterior of the coronary artery proximal to the blockage 28 .
  • the assembly 182 is then advanced through the interior of the coronary artery to create the third channel 178 through the exterior wall 186 of an adjacent coronary vein.
  • a needle delivery assembly can be used to perforate and dilate an access port 200 in the exterior side 18 of the myocardium so as to insert a valved conduit 204 , preferably having a horizontal branch 208 to form a T-shape, into the left ventricle 20 .
  • the valved conduit 204 is positioned so that the branch 208 lies within the myocardium and the end 210 of the valved conduit extends within the left ventricle 20 .
  • the branch 208 is positioned to lie parallel to the myocardium 16 .
  • the valve 212 in the conduit is preferably positioned near the end 210 .
  • an incision can be made along a suitable course in the exterior side 18 of the myocardium such as along the phrenic nerve into the vascular area of myocardium 16 above the left ventricle 20 in front of the coronary artery.
  • the incision is deepened almost to the interior side 24 of the myocardium or the endocardium 202 .
  • a small cavity 206 can be created to assist in the placement of the conduit 204 .
  • a needle assembly is then used to perforate through the endocardium 202 or remaining myocardium below the incision 200 , to the left ventricle 20 .
  • An example of suitable dimensions for the preferred T-shaped valved conduit 204 is about a 4 mm diameter with a vertical branch 214 of about 15 mm and the horizontal branch 208 of about 20 mm long.
  • the horizontal branch 208 is provided to divert blood flow into a direction parallel to the myocardium 16 layer.
  • Other designs for the valved conduit 204 are suitable for use in the present invention.
  • the valved conduit 204 can be a straight stem or have a two horizontal branches in a cross shape.
  • the valved conduit 204 can be made of a porous material that allows blood flow to emanate from the entire length, or selected portions, of the vertical branch 214 and/or horizontal branch 208 .
  • Another preferred method of the present invention is a percutaneous approach which generally introduces a catheter or other guidance/delivery device into the blood source such as the left ventricle.
  • a catheter 220 is placed into the circulatory system 10 at a remote access site such as the femoral artery and advanced through the aortic valve into the left ventricle 20 as illustrated in FIG. 14.
  • the catheter 220 then is directed to the interior side 24 of the myocardium 16 underneath the coronary artery 26 where a penetrating or perforating needle 222 is delivered and advanced from the left ventricle 20 through the myocardium 16 into the coronary artery 26 to create an access port 224 therethrough.
  • valved conduit 226 which is delivered to the access port 224 and inserted into the myocardium 16 .
  • the valved conduit 226 extends completely through the myocardium 16 to create and maintain a channel 42 between the left vertical 20 and the coronary artery 26 distal to the blockage 28 .
  • the locating means can be an ultrasound system, magnetic resonance imaging, computer aided tomography or an echocardiograph.
  • a fluid or medium such as a dye can be introduced by conventional means into the left ventricle 20 that allows its identification by a scanning instrument and provides a background to identify the location of the guided catheter 222 in relation to the coronary artery 26 and the left ventricle 20 .
  • FIGS. 15 and 16 A suitable inventive method using the percutaneous approach is illustrated in FIGS. 15 and 16.
  • a catheter 228 and guide wire 238 are inserted into the coronary artery 26 from a remote access site such as along the femoral artery.
  • the guide wire 238 is used to cross the blockage 28 and then the catheter 228 is inserted over the guide wire and advanced past the blockage.
  • the catheter 228 includes a body 230 having a distal end 232 and proximal end 234 with a window 236 .
  • a guide wire 238 assists in guiding the catheter 228 into the desired position and exchanging a perforating needle 244 and a valved conduit as discussed above.
  • the window 236 is rotated for proper orientation so that the window 236 faces the tissue layer of the coronary artery 26 against the exterior side 18 of the myocardium wherein an access port 248 is to be created.
  • the body 230 includes a balloon 240 which can retractably expand against the inner tissue wall of the coronary artery 26 to hold the window 236 in its proper orientation.
  • the body 230 includes a ramp 242 which directs the perforating needle 244 on a wire into the tissue layer to create the access port 248 .
  • the wire 238 has a hole in its center to provide for back bleeding as means of evidencing the position of the needle 244 .
  • the scanning instrument can determine the position of the needle 244 advancement.
  • the ramp 242 directs the insertion of the valved conduit 250 into the created access port.
  • FIG. 15 Another embodiment of the present invention combines portions of different percutaneous approaches.
  • a guide wire 238 is inserted into the coronary artery 26 from a remote access site such as along the femoral artery.
  • the guide wire 238 is used to cross the blockage 28 and is advanced into the left ventricle 20 .
  • a guide wire is advanced from the same access site into the left ventricle and is used to snare the guide wire 238 advanced from the coronary artery and retrieve the guide wire 238 back to the remote access site.
  • the guide wire 238 completes a circuit from the remote access site through the coronary artery, across the myocardium, to the left ventricle and back to the remote access site.
  • One or more devices can then be advanced through the left ventricle to the interior side of the myocardium without crossing the blockage in the coronary artery.
  • FIG. 17 Another inventive method using the percutaneous approach which advances a catheter 260 into the coronary artery 26 from a remote access site such as along the femoral artery is illustrated in FIG. 17.
  • a penetrating wire 262 is advanced from the catheter to go from the coronary artery and penetrate into an adjacent coronary vein 264 .
  • An excess amount of the penetrating wire 262 is advanced into the coronary vein 264 to assist in retaining the penetrating wire within the coronary vein as the catheter is similarly advanced from the coronary artery 26 into the coronary vein 264 .
  • the position of the catheter 260 is then determined in the coronary vein 264 relative to the left ventricle 20 .
  • the catheter 260 is directed to orient the perforating wire 262 towards the myocardium 16 underneath the coronary vein 264 and to the left ventricle 20 .
  • the perforating wire 262 creates an initial access port 268 through the vascular wall 272 of the adjacent coronary vein 264 and a second access port 270 in the exterior side 18 of the myocardium and completely through the myocardium 16 into the left ventricle 20 .
  • a valved conduit 266 is then inserted into and through the myocardium 16 creating a channel 42 directly from the left ventricle 20 to the coronary vein 264 .
  • the blood flow into the coronary vein 264 is limited to a particular area or section 286 by inserting plugs 274 within the coronary vein on both sides of the initial and second access ports 268 , 270 .
  • the plugs 274 can be moved into their respective positions by insertion through the initial access port 268 .
  • a second conduit 276 is inserted into the initial access port 268 to maintain a second channel 278 between the coronary artery 26 and the coronary vein 264 .
  • blood flows during systole from the left ventricle 20 into the coronary vein 264 and subsequently into the coronary artery 26 distal to the blockage 28 .
  • the coronary vein 264 can provide a temporary reservoir of blood.
  • the valved conduit 266 minimizes backflow of blood from the coronary vein 264 and artery 26 into the left ventricle 20 during diastole.
  • FIG. 18 Another embodiment of this method is illustrated in FIG. 18.
  • the initial access port 268 is offset in its alignment with the second access port 270 A.
  • the catheter 260 is guided to a location either a distance further distal or proximal to the initial access port 268 before the second access port 270 A is created.
  • FIG. 18 specifically illustrates a distal position.
  • the present invention includes still another percutaneous approach wherein transvascular and transmyocardial channels between the left ventricle and coronary artery extend to more than one blood source as illustrated in FIG. 19.
  • An additional access port 280 is created between the coronary artery and the adjacent vein 264 proximal to the blockage 28 in the adjacent coronary artery 26 .
  • the catheter 260 is advanced through the interior of the coronary vein 264 to create the access ports 268 and 270 .
  • a third conduit 282 is inserted into the additional access port 280 to maintain the third channel 284 .
  • One of the plugs 274 is inserted into the coronary vein 264 in a proximal position to the additional access port 280 .
  • a surgical approach can use a catheter in a method similar to that described with reference to FIGS. 14 - 19 . After gaining access to the exterior of the patient's heart and coronary vascular system, the same access area is used to guide the catheter to the coronary vascular system at a location which is significantly closer to the heart.
  • the present invention provides alternate methods of creating the access ports for the surgical and percutaneous approaches described above. Instead of dilating the access ports, a section of tissue can be removed to provide the channel through the myocardium or the vascular tissue.
  • the diameter of the tissue section to be removed is preferably about equivalent to or larger than the diameter of the valved conduit to be inserted.
  • a section of tissue can be removed by mechanical means such as by positioning a rotary drill head or punch at the distal end 32 of the needle assembly in FIG. 2 or the distal end of the delivery device 44 in FIG. 3. As the result, the dilation of the access port is partially or completely obviated.
  • TMR transmyocardial revascularization
  • a laser can be used with either the surgical or percutaneous approaches described herein.
  • the surgical approaches provide adequate space to align the laser from a position external to the heart and vascular system or the laser can be introduced into the left ventricle or coronary system and create a channel from the inside extending outward.
  • a laser fiber can be carried by a guided catheter as described in the methods above.
  • the tissue removal means of the present invention provides channels which are self-maintaining. Channels created by the removal of tissue can avoid the use of a conduit to keep or maintain the channel open.
  • the term self-maintained channel is a passageway through tissue which is open for blood flow from an oxygenated blood source to a selected site during at least a portion of the heart cycle, preferably during systole. With a self-maintaining channel, the regulation of blood is controlled by inserting only a valve, no conduit, into the channel. Or, the self-maintained channel can regulate the flow of blood naturally by orienting the self-maintained channel through the myocardium as described herein.
  • the conduits and valves of the present invention are made of natural vascular tissue or synthetic materials or a combination of both.
  • the synthetic materials are bio-compatible and include metals, alloys and plastics containing one or more polymers.
  • the conventional surgical polymers are suitable plastics. Metals or alloys which are not in themselves bio-compatible can be coated with a bio-compatible metal or plastic.
  • the conduit material is non-porous to blood. However, it is suitable to use material porous to blood and still provide blood flow completely through the length of the conduit.
  • a preferred synthetic conduit 400 is illustrated in FIG. 20 having an elongated body 402 with a cylindrical or tubular shape and a wall 404 having an exterior surface 406 and an interior surface 408 .
  • the wall 404 defines an interior space 410 .
  • the body 402 includes an inlet end 412 for receiving blood from the left ventricle or other oxygenated blood source and an outlet end 414 for delivering the oxygenated blood to a selected site such as a coronary artery or vein.
  • the preferred shape of the cross-section of the body 402 along its longitudinal axis 416 is circular.
  • Other cross-sectional shapes are suitable for use by the present invention such as, for example and not limitation, triangular, rectangular, square, elliptical, oval, and other geometric or free-form shapes.
  • the cross-sectional size is illustrated as uniform across the length of the body 402 . However, the cross-sectional size can vary along the length of the body 402 , or taper or flare the body 402 near the ends 412 and 414 .
  • the diameter of the conduit 400 is preferably not expandable and is inserted into the channel 42 as a predetermined size without the need to expand the diameter of the body 402 .
  • the body 402 resists compressive forces placed on it by the myocardium during the heart cycle to maintain the channel 42 in the open position.
  • the present invention also provides for using conduits with a diameter which is expandable after insertion into the myocardium.
  • the length of the conduit 400 is sized to be longer than the maximum width the myocardium achieves during the heart cycle.
  • the conduit 400 extends beyond the exterior side 18 and interior side 24 defining the myocardium and slightly into the left ventricle 20 and coronary artery 26 . It is suitable to provide the length of the conduit 400 so that one end is approximately flush with the interior side 24 and/or exterior side 18 of the myocardium.
  • the conduit 400 includes projections 418 integrally formed with the body 402 near the inlet end 412 and outlet 414 means for retaining the conduit in position once it has been inserted within the myocardium 16 or other tissue layer.
  • the projections 418 can have an end 420 which is barbed or otherwise shaped for slightly penetrating, embedding, or abutting the myocardium 16 in the area surrounding the ends 412 and 414 .
  • the connection between the body 402 and the projections 418 includes a spring bias which allows the projections 418 to fold relatively flat against the exterior surface 406 of the body while the conduit 400 is being inserted into the channel 42 through the myocardium 16 or tissue layer.
  • the projections 418 then relax to their outwardly extended position once the ends 412 , 414 of the conduit extend into the left ventricle 20 and coronary artery 26 and are clear of the channel 42 .
  • the spring bias can be supplied by conventional memory or superelastic materials.
  • the synthetic conduit 400 includes a valve 422 having flaps 424 which open to allow blood flow in one direction from the left ventricle 20 to the coronary artery 26 and close to minimize the backflow of blood in the reverse direction.
  • the closure of the flaps 424 need not completely seal the interior space 410 .
  • the valve 422 can be supported by a ring 426 inserted within the interior space 410 so as to abut the interior surface 408 as a component separate from the body 402 .
  • the valve 422 can be integrally formed with the wall 404 .
  • FIG. 21 illustrates projections 430 which are initially retracted into the interior space 410 through slots 432 in the wall 404 .
  • the connection between the body 402 and the projections 430 includes a spring bias which allows the projections 430 to retract into the interior space 410 of the body while the conduit 400 is being inserted into the channel 42 through the myocardium 16 or tissue layer.
  • the projections 430 then released to their outwardly extended position once the conduit 400 is in the desired position.
  • This embodiment also illustrates that the projections 430 slightly penetrate the face 434 of the channel 42 rather the area of the myocardium surrounding the channel.
  • FIG. 22 Another example of the retaining means provided by the present invention include forming a screw thread 436 on the exterior surface 406 of the body as illustrated in FIG. 22.
  • the thread 436 is of sufficient size and quantity to hold the conduit 400 in the desired position by biting into the face 434 of the channel.
  • the thread 436 can extend over one or more sections of the exterior surface 406 .
  • the thread 436 need not be continuous and can be positioned anywhere along the length of the exterior surface 406 .
  • FIG. 23 illustrates the inlet end 412 being flared 438 so that its diameter is greater than the diameter of the channel 42 .
  • the flared end 438 extends beyond the myocardium 16 layer.
  • the end 438 can be flared prior to or after insertion of the conduit 400 into desired position.
  • FIG. 24 illustrates the inlet end 412 being effectively expanded by a coating 440 applied to the exterior surface 406 of the conduit near the end.
  • the coating 440 expands after insertion 440 A to hold the conduit 400 in the desired position.
  • an adherence between the exterior surface 406 of the conduit and the face of the myocardium along the channel can be promoted to retain the conduit in the desired position.
  • at least a portion of the length of the conduit 400 can be coated on the exterior surface 406 with a bio-compatible adhesive which assists the adherence with the face of the myocardium.
  • Another example is to abrade the exterior surface 406 of the conduit.
  • FIG. 25 illustrates that the retaining or anchoring means can be located anywhere along the length of the body 482 of the conduit 480 such as the middle section 484 .
  • Another type of anchoring means is also illustrated in the form of elongated slots 486 .
  • the face of the myocardium along the channel may embed into the areas of the slots 486 to retain the conduit in the desired position.
  • the retaining means can also be useful in sizing the length of a conduit immediately after insertion through the myocardium. For example, using the surgical approach described in reference to FIG. 4, a conduit having a length significantly longer that the myocardium's maximum width can be inserted through the coronary artery and into the myocardium.
  • the end of the conduit extending into the left ventricle includes a retaining means. Once the resistance of the retaining means is felt by attempting to withdraw the conduit, the excess length of the conduit extending out of the myocardium and through the coronary artery is cut off.
  • FIGS. 26A and 26B illustrate another example of the conduit 400 provided by the present invention wherein the inlet end 412 is flared 438 and the outlet end 414 have projections 442 which slightly penetrate into the area of the myocardium 16 surrounding the channel 42 . During systole, the thickness of the myocardium 16 is near its greatest during the heart cycle. As illustrated in FIG. 26A, the outlet end 414 of the conduit extends slightly into the coronary artery 26 and is retained in positioned by being anchored to the exterior side 18 of the myocardium.
  • the length of the conduit 400 is predetermined so that the inlet end 412 of the conduit also extends slightly into the left ventricle 20 when the myocardium 16 is thickest during the heart cycle.
  • the inlet end 412 can be flared 438 so as to further assure retaining the interior side 24 of the myocardium to provide at least a slight extension of the inlet end 412 into the left ventricle 20 .
  • the thickness of the myocardium 16 decreases.
  • the outlet end 414 is anchored on one side of the conduit allowing the remainder of the myocardium to slide along the longitudinal axis 416 of the conduit.
  • the inlet end 412 is not specifically anchored and is free to extend further into the left ventricle 20 during diastole.
  • FIG. 27 illustrates the conduit 400 with at least a two telescoping components 444 , 446 which slidably insert into one another as indicated by arrow 445 .
  • Both the inlet end 412 and the outlet end 414 retain the myocardium in the desired position by anchoring the ends with projections 442 to the interior side 24 and exterior side 18 of the myocardium, respectively.
  • the component 446 slides within component 444 in a telescoping manner to adjust to the changing thickness of the myocardium.
  • the length of the telescoping components 444 , 446 are predetermined so that they remain within each other all through the heart cycle.
  • FIG. 28 provides the conduit 400 with an accordion section 456 which expands and contracts in a longitudinal direction as indicated by arrow 457 while providing resistance against radial compression.
  • Each end 412 and 414 retain the myocardium in the desired position by anchoring the ends with projections 442 to the interior side 24 and exterior side 18 of the myocardium, respectively.
  • the two ends 412 , 414 move towards each other during diastole and away from each other during systole with the accordion section 456 respectively contracting and expanding in a longitudinal direction.
  • FIG. 29 illustrates another accordion section 458 which reversibly expands in a latitudinal direction.
  • Each end 412 and 414 retain the myocardium in the desired position by anchoring the ends with projections 442 to the interior side 24 and exterior side 18 of the myocardium, respectively.
  • the two ends 412 , 414 move towards each other during diastole and away from each other during systole with the accordion section 458 respectively contracting and expanding in a latitudinal direction as indicated by arrows 460 .
  • the latitudinal accordion section 458 not only maintains and regulates blood flow through the channel, but also provides a temporary reservoir of blood in the accordion section 458 itself.
  • the valve 422 can be placed at either end 412 , 414 or valves placed at both.
  • FIG. 30 Another example of the adjusting means of the present invention is illustrated in FIG. 30 wherein the conduit 400 includes at least two components 448 , 450 which form a body 402 which is discontinuous. Each end 412 and 414 retains the myocardium 16 in the desired position by anchoring the ends with projections 442 to the interior side 24 and exterior side 18 of the myocardium, respectively.
  • the valve 422 can be included in either component 488 or 450 . With the components 448 , 450 positioned perpendicular to the myocardium width, the two components 448 , 450 move towards each other during diastole and away from each other during systole when the heart cycles as indicated by arrow 452 . Without support from either component 448 , 459 , a section 454 of the channel between the-two components 448 , 450 is self-maintained in the open position.
  • FIG. 31 illustrates an example of an adjusting means wherein the conduit 400 includes a body 402 made of a continuous coil 462 which expands and contracts along its longitudinal axis to accommodate the changing thickness of the myocardium 16 during the heart cycle while resisting radial compression.
  • the outer periphery 464 of the coil 462 slides along the face 466 of the myocardium defining the channel 42 .
  • the coil 464 is anchored to the myocardium 16 at the inlet end 468 and outlet end 470 by projections 472 which are supported by rings 474 connecting to respective ends of the coil 464 .
  • gaps 476 are formed between the outer periphery 464 of individual spirals or the gaps 476 increase in size if the gaps already exist when the coil 462 is at its maximum level of relaxation during systole. Should the face 466 of the myocardium adhere to the outer periphery 464 of one or more individual spirals, either immediately after insertion into the channel or as a long-term effect, the remaining spirals provide expansion by moving along the longitudinal axis.
  • a T-shaped conduit 490 includes a branch 492 allowing the continued flow of blood or prevents the stasis of blood proximal to the conduit in the coronary artery 26 .
  • FIG. 33 illustrates a hook-shaped conduit 494 having a right-angle bend toward the direction of desired blood flow.
  • the outer periphery 496 of the conduit outlet end can be sized to have the coronary artery dilated over its edge or can be smaller than the diameter of the coronary artery.
  • FIG. 34 illustrates a hybrid, synthetic/natural conduit 497 which includes a section of vascular tissue 498 attached to a synthetic segment 499 .
  • the vascular tissue 498 is attached 495 to the wall 493 of the coronary artery by conventional closure means such as suturing. In this embodiment, no section of the conduit 497 extends into the coronary artery.
  • the present invention also provides a naturally valved conduit such as a vein or other vascular tissue which is preferably autologous.
  • a conduit made from the vein can be all natural or include synthetic materials in combination with the vein.
  • a preferred combination conduit 500 combines a vein 502 which is at least partially supported by a synthetic cage 504 having an elongated body 506 with a cylindrical or tubular shape and longitudinal members 508 having an exterior surface 510 and an interior surface 512 .
  • the cage 504 defines an interior space 514 .
  • the body 506 includes end members 516 connected to the longitudinal members 508 .
  • the cage 504 includes projections 518 which, as previously described, retain the conduit 500 in the desired position with the myocardium.
  • the vein 502 is extended along the interior surface 512 through the interior space 514 of the conduit.
  • the ends 520 of the vein 502 are stretched over end members 516 and back in the reverse direction to secure the vein 502 to the cage 504 .
  • a suture can be placed through the end 520 and the wall 528 of the vein.
  • the vein 502 defines an inlet end 522 for receiving blood from the left ventricle or other oxygenated blood source and an outlet end 524 for delivering the oxygenated blood to a selected site such as a coronary artery or vein.
  • the present invention regulates the flow of blood through the conduit 500 utilizing the flaps and wall movement of the vein which are inherent, natural properties of the vein 502 .
  • the natural valving function of the vein 502 is preserved by allowing the wall 528 of the vein to move towards itself or substantially collapse upon itself as indicated by arrows 526 .
  • FIG. 36 Another embodiment of the combination conduit 500 is illustrated in FIG. 36.
  • the cage 504 includes a second pair of end members 530 spaced in a parallel relationship to the end members 516 and connected to the longitudinal members 508 .
  • Each end 520 of the vein 502 is inserted in a press fit between one of the end members 516 and second end members 530 to secure the vein 502 to the cage 504 .
  • Other means of securing the vein 502 to the cage 504 are also suitable such as be suturing the ends 520 of the vein to the end members 516 with a continuous suture or a plurality of individual sutures.
  • FIG. 36 also illustrates another example of positioning the vein 502 along the exterior side 510 of the cage. As indicated in phantom 528 A, the wall 528 moves toward itself or substantially collapses upon itself to preserve the natural valving of the vein 502 .
  • the present invention provides other types of valves for regulating the flow of blood through a conduit or a self-maintained channel.
  • One valve type as used in the Examples herein, is similar to a Starling resistor and illustrated in FIG. 37.
  • the conduit 550 includes a rigid, elongated body 552 having an inlet end 554 which extends into the left ventricle 20 .
  • the body 552 extends substantially through the myocardium 16 .
  • a valve 558 On the outlet end 556 of the body is attached a valve 558 having a tubular body 560 made of a pliable material which extends into the coronary artery 26 distal to the blockage 28 .
  • the pliable material can be a section of vein.
  • the tubular body 560 is sufficiently flexible to collapse on itself.
  • a cage 548 can be inserted into the coronary artery 26 in the area of the tubular body 560 to assist in preventing the collapse of the artery in that area.
  • FIGS. 38A and 38B Another example of the valves provided by the present invention is illustrated in FIGS. 38A and 38B.
  • a conduit 560 extends completely through the myocardium 16 and slightly into the left ventricle 20 and the coronary artery 26 .
  • the conduit 560 includes at least one segment 562 that is made of a pliable material which resists compression by small radial forces but which collapses as seen in FIG. 38B during a portion of the heart cycle.
  • the conduit 560 is orientated at an obtuse angle to the interior side 24 and exterior side 18 of the myocardium and to the direction of change in the thickness of the myocardium.
  • the present invention provides a self-maintained channel 600 defined by a face 602 of the myocardium 16 as illustrated in FIG. 39.
  • the channel 600 extends completely through the myocardium 16 in a perpendicular direction from the left ventricle 20 on the interior side 24 to the coronary artery 26 on the exterior side 18 .
  • the channel 600 is created by removing tissue so that it remains at least partially open during the cycle of the heart.
  • the self-maintained channel 600 includes a valve 604 inserted within the channel as illustrated in FIGS. 39 and 40.
  • the valve 604 includes interleaved flaps 606 supported on a body 608 .
  • the valve 604 is not associated with a conduit.
  • the width of the body 608 is preferably the minimum size required to provide support and orientation for the flaps 606 and not particularly to maintain the channel 600 open.
  • the flaps 606 are set to open during positive pressure exerted by blood flow in the direction from the left ventricle 20 to the coronary artery 26 . Negative pressure or blood flow in the reverse direction at least partially closes the flaps 606 to minimize the flow of blood to the left ventricle 20 .
  • the body 608 includes a periphery 610 having a thread 612 integrally formed along the periphery.
  • the thread 612 includes a starting edge 614 for engaging the face 602 and slightly dilating the diameter of the myocardium 16 . As the periphery 610 is rotated, the starting edge 614 assists the advance of the thread 612 into contact with the face 602 of the myocardium.
  • the thread 612 can slightly embed itself or slightly penetrate into the face 602 of the myocardium to retain the valve 604 in the self-maintained channel 600 .
  • Another example of a mechanical means for regulating blood flow is to use a material in place of the flaps 606 which is semi-permeable to blood flow.
  • the semi-permeable material can allow the blood to flow from the left ventricle while minimizing the reverse flow of blood.
  • the present invention also provides self-maintained channels which regulate the flow of blood without a synthetic valve as illustrated by the examples in FIGS. 41 and 42.
  • Self-maintained channel 620 extends completely through the myocardium 16 from the left ventricle 20 to the coronary artery 26 .
  • the channel 620 includes two segments 622 and 624 which are orientated at an obtuse angle to the interior side 24 and exterior side 18 of the myocardium, respectively.
  • a third segment 626 connects to the other segments 622 , 624 and is orientated in a generally parallel direction relative to the sides 24 , 18 of the myocardium and-a perpendicular direction to the change in the thickness of the myocardium.
  • each of the segments is affected differently by forces applied by the surrounding myocardium as it contracts and relaxes during the cycle of the heart.
  • the forces from the myocardium can change both the length and diameter of the segments 622 , 624 , and 626 .
  • the flow of blood is minimized into the left ventricle 20 during the cycle of the heart.
  • arrows indicate only a general movement of the myocardium 16 in changing thickness during the heart cycle. There are forces experienced during the heart cycle within the myocardium 16 which are not strictly orientated perpendicular to the coronary artery and left ventricle.
  • FIG. 42 Another example of a self-maintained channel which regulates the flow of blood therethrough with the natural rhythmic cycle of the heart is illustrated in FIG. 42.
  • the self-maintained channel 640 includes a bowed or curved configuration which extends completely through the myocardium 16 from the left ventricle 20 to the coronary artery 26 .
  • the forces applied by the surrounding myocardium as it contracts and relaxes during the cycle of the heart can be advantageously used to regulate the flow of blood through the channel 640 .
  • the forces from the myocardium can change both the length and diameter of the channel 640 . As a result, the flow of blood is minimized into the left ventricle 20 during the cycle of the heart.
  • the first set of experiments was carried out on seven female Yorkshire pigs weighing 30-35 kg. On four of the pigs, a formal sternotomy was used and in the other three pigs, a left anterior 4 th intercostal space thoracotomy was used. A prototype conduit was introduced into the left ventricle through a formal sternotomy with the other end of the conduit introduced into the left anterior descending coronary artery through cannualation. The left anterior descending coronary artery was then tied proximally. In this set of experiments, blood flow was delivered to the proximally occluded left anterior descending artery from the left ventricular chamber through a valved conduit, there being no other blood supply to the left anterior descending coronary artery.
  • valves were incorporated within the conduit. These valves consisted of a fine penrose tube or an IMA vein suspended between two ports in a chamber which could be pressurized. The IMA vein would be harvested shortly before and have about a 2 cm length with one or two valves. When connected in this fashion, blood passed in a continuous path from the left ventricular chamber via the penrose tube or vein into the left anterior descending coronary artery. The surrounding chamber could then be pressurized to any pre-determined level and in this way, the penrose tube or vein would collapse and prevent backflow when left ventricular pressure fell below the pressurized chamber level.
  • the penrose tube or vein functioned in a manner commonly referred to as a “Starling resister” similar to that illustrated in FIG. 20.
  • Another valve type employed a small penrose tube or a vein segment Which was suspended from only one port in a non-pressurized chamber with a second opening in the chamber allowing continuity of blood flow from the left ventricle to the left anterior descending artery.
  • Each harvested vein graft was inserted between the two catheters, creating a valved conduit approximately 15 mm long with an overall length of about 10 cm for complete external pathway.
  • any attempt at backflow of blood to the left ventricular chamber would cause collapse of the penrose tube or vein segment and occlude the backflow port.
  • the second set of experiments were designed to evaluate the net coronary flow per minute whether delivered in systole or diastole, under control conditions and compared these to the net coronary flow in mL/min delivered from the left ventricle as the only source (all proximal coronary arteries having been ligated.)
  • this set of experiments six England pigs weighing 30-35 kg underwent surgical stemotomy and cannulation of the coronary sinus—the common outflow of all coronary blood flow.
  • the left hemiazygous vein was ligated so that coronary sinus blood was not contaminated by the systemic circulation.
  • all blood flow emanating from the coronary sinus was collected for a specific period of time and the mL of coronary blood flow per minute calculated.
  • a left ventricular conduit was then surgically inserted into the left ventricular chamber from the epicardial surface and then connected to cannulas which had been inserted into the left and right coronary os.
  • the left ventricle was the only source for coronary blood flow.
  • coronary blood flow therefore originated from the left ventricle and passed through a prototype conduit and valving system as described above into the right coronary os and left coronary os. Measurement of total coronary blood flow emanating from the coronary sinus under this condition demonstrated no difference in net coronary blood flow per minute from the control condition.
  • the dynamic motion of heart muscle and subsequent motion of the conduit may reduce stasis which contributes to clot formation.
  • the high velocity of delivery from the left ventricle to the coronary artery may reduce incidence of clot formation and resulting thrombosis (occlusion).
  • the short length of the conduit (approximately 15 mm) may reduce the chance of clot formation and thrombosis (occlusion).
  • the present invention provides significant advantages when compared to the prior art relating to interventional procedures such as the ability to improve long term patency rates and reduce the high rate of retreatment. Furthermore, the present invention allows multiple vessels to be treated. Compared to CABG surgery, the present invention is a less-invasive procedure which can be performed on a beating heart using smaller incisions for entry than normally required by conventional techniques. Also, harvesting an autologous graft may not be needed.
  • the present invention fulfills many needs found wanting in the prior art. Many patients were not candidates for percutaneous or CABG surgery because they could not be fully revascularized by the surgery. The present invention significantly enlarges the population of potential candidates. Furthermore, the use of small ports between the ribs to provide the revascularization provides an access site in the immediate vicinity of the selected site in the arterial vascular system and avoids the use of a sternotomy and/or a thoracotomy. The present invention provides access to the arterial vascular system on both sides of the heart such as the left anterior descending artery, circumflex artery, and as well as their tributaries.
  • the present invention fulfills many clinical needs that are currently unmet by the prior art. For example, many patients with coronary artery disease are not amenable to CABG or percutaneous treatment due to their extensive disease. However, this invention offers a comparable treatment alternative to conventional techniques allowing these patients to receive care. Furthermore, the inventive approach provides for methods and devices that allow for coronary revascularization procedures to be performed through small holes instead of a chest incision. The present invention provides access to the arterial vascular system allowing for all vessels of the heart to be revascularized.
  • the present invention also provides for partial revascularization or increased flow by having a self-maintained channel or conduit without a valve.
  • a channel is created and maintained between an oxygenated blood source and a site selected in the arterial vascular system.
  • the channel does not incorporate means for regulating the blood flow therethrough. More particularly, when the selected site is distal to a substantial or complete blockage or occlusion, a self-maintained channel or conduit without a valve between the left ventricle and selected site provides significant, but not complete, revascularization of the selected site and the surrounding area.

Abstract

This invention relates to methods and devices providing transmyocardial blood flow or coronary revascularization for the treatment of coronary atherosclerosis and resulting myocardial ischemia by increasing the flow of blood from one or more oxygenated blood sources within the patient to one or more sites selected in the arterial vascular system of the heart using a channel for maintaining and regulating blood flow therebetween. A valved conduit or a self-maintained channel is created between the left ventricle reservoir of oxygenated blood and the coronary artery distal to an area of obstruction by surgical and percutaneous methods. Preferably, the conduit or self-maintained channel integrally regulates the flow of blood between the oxygenated blood source and the site selected in the arterial vascular system of the heart wherein an increase in blood flow is desired.

Description

    FIELD OF THE INVENTION
  • This invention relates to methods and devices providing transmyocardial blood flow or coronary revascularization for the treatment of coronary atherosclerosis and resulting myocardial ischemia. The invention increases the flow of blood from one or more oxygenated blood sources within the patient to one or more sites selected in the arterial vascular system of the heart using a channel for maintaining and regulating blood flow therebetween. More particularly, a valve is inserted into a channel created and maintained between, or a valved conduit is inserted between, the left ventricle reservoir of oxygenated blood and the coronary artery distal to an area of obstruction. [0001]
  • BACKGROUND OF THE INVENTION
  • Heart disease is a major medical ailment wherein arteries become narrowed or blocked with a build-up of atherosclerotic plaque or clot which reduces flow to tissues downstream or “distal” to the blockage. When this flow reduction becomes significant, a patient's quality of life may be significantly reduced. In fact, heart disease patients often die when coronary arteries become significantly blocked. [0002]
  • However, technology has been developed to treat patients with coronary artery disease. Besides drug treatment, the two most common operative procedures used to treat symptomatic patients are: coronary artery bypass graft (CABG) surgery and percutaneous transluminal coronary angioplasty (PTCA). [0003]
  • Conventional CABG surgery affixes a bypass graft between a port or aperture in a coronary artery wall distal to the blockage and a pressurized arterial blood supply, such as the aorta, to provide a conduit for blood flow into the coronary artery to the ischemic areas of the heart. CABG surgery is generally initiated by directly exposing the heart to the surgeon by opening the patient's chest using known sternotomy and retraction techniques that cut the sternum and spread the rib cage open. Once the heart is exposed, the patient is connected to a cardiopulmonary bypass (“CPB”) machine so that the blood supply circumvents the heart. In this way, the heart is depressurized so that apertures can be cut into the walls of the vessels for surgical graft attachment. The right atrium (or vena cava) and the aorta each is intubated with cannulas which are connected to an artificial pump and oxygenator. Once these major vessels are cannulated, the aorta is then clamped proximally of the aortic bypass cannula, thereby isolating the aortic root and heart from the blood that is being circulated by the CPB. Cardioplegia is then delivered to stop the beating motion of the heart. [0004]
  • In one type of CABG method, the bypass grafting is achieved between the aorta and one of the three major coronary arteries or their sub-branches, the left anterior descending artery (LAD), the circumflex artery (CIRC), or the right coronary artery (RCA). In such a case, a saphenous vein is usually taken from the patient's leg and is transplanted as a “homograft” to connect these vessels in order to provide blood flow to the compromised area of the coronary circulation. Artificial grafts have also been disclosed as providing potential utility for this purpose. An alternative CABG method uses the internal mammary artery (IMA) alone or in conjunction with the saphenous vein graft. The IMA is severed at a chosen location and is then connected to an aperture, in a coronary artery. The fluid connections between a graft and a vessel are commonly referred to as “anastomoses.” Once the anastomosis of the bypass graft is complete, the heart is resuscitated and the patient is removed from CPB. [0005]
  • Although CABG surgery grafts have good long patency rates of about 60% to 90% over a ten year period, the isolation of the heart with the CPB and aortic cross-clamp carries a significant risk of mortality. It is believed that three critical determinants which affect outcomes of CABG surgery are: (1) time the patient spends on bypass, (2) time the patient spends with a clamped aorta, and (3) the quality of the anastomoses. It is generally believed that a CABG patient's operative and peri-operative morbidity are directly related to how long the patient must be on CPB. During prolonged periods on CPB, there is a greater chance for air and platelet embolization resulting from the artificial circuit. For example, such debris can embolize into the neurovasculature and potentially cause a stroke. In analyzing the timing of individual CABG steps against the backdrop of a patient's critical time on CPB, the time spent anastomosing the grafts to vessels emerges as a controlling factor. Closely related to the time spent on CPB is a second CABG success factor related to the extent and time of aortic cross-clamping. It is believed that the inherent crushing force from a cross-clamp across the bridge of the muscular aortic arch may be associated with a high degree of tissue trauma and structural damage. Additionally, blood clots formed at or adjacent to the cross clamp, perhaps in conjunction with the tissue trauma of clamping, may also be a source of unwanted complications. In addition to the potential clinical complications associated with CABG surgery is also the cost of the time-consuming procedure. [0006]
  • In the PTCA procedures, a small incision is made in the patient's thigh to introduce a catheter into the femoral artery. The catheter is guided to the internal blockage site via x-ray visualization. The blockage is then treated remotely by use of hydraulic pressure in the case of balloon angioplasty wherein a balloon is inflated within the narrowed vessel to stretch or otherwise deform the blockage into a larger lumen. Or, in the case of atherectomy, other actuating means can be used to cause remote cutting or ablation of the blockage. In another approach, a stent is used to scaffold open the blocked area of the artery. Although these procedures are less traumatic than CABG surgery, the failure rate is often about 30-50% whereby the vessel narrows within a six month period and must be treated again. [0007]
  • Due to the limitations with these operative techniques, alternate methods have been proposed. For example, U.S. Pat. No. 5,655,548 by Nelson et al. discloses open surgical and transluminal methods for supplying long-term retrograde perfusion of the myocardium via a conduit disposed between the left ventricle and the coronary sinus. Blood ejected from the left ventricle enters the coronary sinus during cardiac systole. The outlet from the left ventricle to the coronary sinus may include a one-way valve to prevent backflow from the coronary sinus into the left ventricle during cardiac diastole. The long-term artero-venous fistula that is created, however, has the potential for edema or other physiologic effects. [0008]
  • Another alternate method is disclosed in international patent applications: WO 97/27897, WO 97/27893, WO 97/13463, WO 97/13471, and WO 97/27898; wherein a percutaneous, transluminal approach is described which requires an adjacent cardiac vein to perform the procedure. Unfortunately, most coronary arteries do not have adjacent cardiac veins and, thus, the disclosed approach may be limited in its ability to provide full revascularization. [0009]
  • Another method is disclosed by Wilk in U.S. Pat. Nos. 5,429,144, 5,287,861, 5,662,124 and 5,409,919, wherein an expandable stent is disposed in the myocardium by a percutaneous approach through the coronary artery requiring no incision through the chest. The method requires that the expandable stent be initially collapsed, ejected from a catheter into the myocardium, and subsequently expanded with an inflatable balloon in the myocardium. The expandable stent extends only partially through the myocardium, from the left ventricle of the heart or from a coronary artery, upstream of a vascular obstruction. Alternatively, the expandable stent can extend through the myocardium between the left ventricle and the coronary artery, but is completely within the myocardium and not extending into either the left ventricle or coronary artery. The purpose of the expandable stent is to establish blood flow to the myocardium, and in some instances, to the coronary artery. One design of the expandable stent is to collapse and close during systole. In an alternate design, the expandable stent can resist the contractive pressure of the heart to remain open during systole to permit the flow of blood through the stent into the myocardium and coronary artery. During diastole, the blood pumped into the coronary artery through the expandable stent can be blocked from returning to the left ventricle by an integrated, one-way valve. [0010]
  • Among the drawbacks in using the Wilk method is that the stent must be expandable and any valve therein must be integral with the stent. The expandable stent is also sized to be only within, and not beyond, the myocardium. The expandable stent fails to accommodate changes in the thickness of the myocardium wall during the rhythmic contraction of the heart which, according to Feigenbaum's textbook of Echocardiography, changes from an average thickness of about 8 mm in diastole to about 13 mm in systole. The transluminal approach disclosed by Wilk can also have difficulty in delivering the expandable stent across coronary arteries which are substantially occluded. Approximately 60% of CABG surgery procedures are performed on totally occluded vessels where percutaneous access would not be feasible. [0011]
  • Ever since the discovery by Wearn, as reported in the “The Nature of the Vascular Communications Between the Coronary Arteries and the Chambers of the Heart”, American Heart Journal, Volume 9, Number 2, 1933, that the myocardium is composed of a vast, sinusoidal network, people have attempted to revascularize the heart muscle directly. In 1957, Massimo and Boffi reported experiments in the Journal of Thoracic Surgery, [0012] Volume 34, Number 2, with T-shaped tubes that were implanted directly into the myocardium in order to maintain a fluid channel between the left ventricle and myocardium. Another approach pioneered by Vineberg, “Coronary Vascular Anastomoses by Internal Mammary Artery Implantation”, Canad. M. A. J., Volume 78, Jun. 1, 1958, focused on the implantation of the IMA directly into the myocardium. In 1965, Sen et al., “Transmyocardial Acupuncture”, Journal of Thoracic and Cardiovascular Surgery, Volume 50, Number 2, 1995, performed transmyocardial acupuncture which became the precursor to laser-assisted transmyocardial revascularization (TMR) in 1986, wherein multiple laser pin holes are made in the compromised myocardial area and into the left ventricle. However, these holes do not maintain a channel between the left ventricle and the native coronary circulation. Also, these holes are not maintained in an open state once they are formed. It is surmised that the benefit of the TMR approach is that it stimulates angiogenesis (new vessel growth) rather than maintaining new channels of perfusion.
  • There have been several studies that clearly teach away from the transmyocardial arterial revasculation described in the present invention. In a study similar to Sen et al., the authors Pifarre et al., reported in “Myocardial Revascularization by Transmyocardial Acupuncture: A Physiologic Impossibility”, Journal of Thoracic and Cardiovascular Surgery, Volume 58, Number 3, 1969, attempts to revascularize the myocardium by coring out sections of the muscle to create a left ventricle to myocardial connection. They concluded that “. . . no blood flow is possible from the ventricle to the myocardium.”[0013]
  • Another article “The Possibility of Myocardial Revascularization by Creation of a Left Ventriculocoronary Artery Fistula” by Ian Munro and Peter Allen, Journal of Thoracic and Cardiovascular Surgery, Volume 58, Number 1, 1969, discloses an attempt to revascularize an ischemic myocardium by constructing a fistula between the cavity of the left ventricle and the coronary circulation. Two conclusions drawn from the experimental results again teach away from the present invention. “First, any attempts to revascularize the wall of the left ventricle direct from the cavity of the ventricle are likely to be functional failures, even if technically successful . . . In addition, there was a failure of myocardial contractility and a rise in left ventricular and diastolic pressure. It was concluded that operations designed to revascularize the myocardium direct from the cavity of the left ventricle make the myocardium ischemic and are unlikely to succeed.”[0014]
  • While other attempts have been made to reduce the complications associated with “CABG” surgery through less-invasive, standard surgical approaches, they have been limited in their ability to fully revascularize the heart and provide a comparable degree of long-term success. The prior art fails to disclose or fulfill the need for transmyocardial blood flow or coronary revascularization using a beating heart approach with either surgical or percutaneous techniques to create and maintain one or more regulated channels between the left ventricle and the arterial vascular system of the heart. The present invention also potentially eliminates the need for harvesting autologous bypass graft material that can be in short supply, contributes to the morbidity of the CABG procedure, and can compromise the vascular system. [0015]
  • SUMMARY OF THE INVENTION
  • The present invention provides a method for increasing the flow of blood to a selected site in a patient's arterial vascular system of the heart. The method includes the steps of: creating a channel for blood flow from an oxygenated blood source to the selected site in the arterial vascular system of the heart; maintaining the channel in an open position for blood flow through diastolic and systolic cycles of the heart; and regulating the blood flow in the channel to minimize blood flow from the coronary vascular system to the blood source during diastolic cycle of the heart. [0016]
  • The present invention also provides a method for performing a transmyocardial coronary revascularization procedure for the treatment of coronary atherosclerosis caused by an obstruction in the arterial vascular system. The method includes the steps of: creating a channel for blood flow from an oxygenated blood source to the arterial vascular system distal to the area of obstruction; maintaining the channel in an open position for blood flow through the diastole and systole cycles of the heart; and regulating the blood flow in the channel to minimize blood flow from the arterial vascular system to the blood source during the diastolic cycle of the heart. [0017]
  • A method for treating an obstruction in a patient's cardiovascular system using a non-expandable conduit made of biocompatible material is also provided by the present invention. The method includes the steps of: inserting the conduit completely through the myocardium of the patient's heart with one end of the conduit extending into the left ventricle and the other end of the conduit extending into the arterial vascular system distal to the area of obstruction; maintaining the conduit in an open position for blood flow through the diastolic and systolic cycles of the heart; and regulating the blood flow in the channel to minimize blood flow from the arterial vascular system to the left ventricle during the diastolic cycle of the heart. [0018]
  • Another method provided by the present invention increases the flow of blood to a selected site in a patient's arterial vascular system. The method includes the steps of: inserting one end of a conduit into the left ventricle; inserting the second end of the conduit into the arterial vascular system at the selected site; maintaining the conduit in an open position for blood flow through the diastolic and systolic cycles of the heart; and regulating the blood flow in the conduit to minimize blood flow from the arterial vascular system to the left ventricle during the systolic cycle of the heart. [0019]
  • The present invention also includes conduits for maintaining a channel between an oxygenated blood source and a site in the arterial vascular system of the heart selected for delivering an increase of blood flow thereto. The conduit includes a tubular body having an inlet end and outlet end between the blood source and selected site, respectively. Preferably, the conduit includes means for regulating the flow of blood between the blood source and selected site. The conduit can include means for retaining the conduit in the myocardium with the inlet end extending into the left ventricle. Optionally, the conduit includes means for adjusting the conduit to the change of thickness of the myocardium during the heart cycle. [0020]
  • The present invention also provides a self-maintained channel created between an oxygenated blood source and a site in the arterial vascular system of the heart selected for delivering an increase of blood flow thereto. The self-maintained channel maintains an open position during at least a portion of the heart cycle. The self-maintained channel includes an inlet end and outlet end between the blood source and selected site, respectively. Preferably, the self-maintained channel includes an integral means for regulating the flow of blood between the blood source and selected site. Optionally, the self-maintained channel includes a natural or synthetic valve positioned therein as the regulating means.[0021]
  • BRIEF DESCRIPTION OF THE DRAWING
  • FIG. 1 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created from the left ventricle to a coronary artery in accordance -with the present invention; [0022]
  • FIG. 2 is a side view of another embodiment of the needle assembly illustrated in FIG. 1 for creating and dilating an access port in the myocardium or other tissue layer in accordance with the present invention; [0023]
  • FIG. 3 is a side view of a delivery assembly for inserting a conduit into the myocardium or other tissue layer in accordance with the present invention; [0024]
  • FIG. 4 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery to the left ventricle in accordance with the present invention; [0025]
  • FIG. 5 is an integrated assembly to perforate, dilate, and insert a conduit into a channel in the myocardium or other tissue layer in accordance with the present invention; [0026]
  • FIG. 6 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery and the left ventricle in accordance with the present invention; [0027]
  • FIG. 7 is another embodiment of an integrated assembly to perforate, dilate, and insert a conduit into a channel in the myocardium or other tissue layer in accordance with the present invention; [0028]
  • FIG. 8 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery, both distal and proximal to a blockage, and to the left ventricle in accordance with the present invention; [0029]
  • FIG. 9 is a schematic cross-sectional view of a human heart showing a conduit inserted by a surgical method into a channel created along an extended portion of the myocardium from a coronary artery, both distal and proximal to a blockage, and to the left ventricle in accordance with the present invention; [0030]
  • FIG. 10 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery to a coronary vein and into the left ventricle in accordance with the present invention; [0031]
  • FIG. 11 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a surgical method into a channel created from a coronary vein into both a coronary artery and the left ventricle in accordance with the present invention; [0032]
  • FIG. 12 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a surgical method into a channel created from a coronary artery, both distal and proximal to a blockage, through a coronary vein and into the left ventricle in accordance with the present invention; [0033]
  • FIG. 13 is partial cross-sectional view of a conduit positioned within the myocardium in accordance with the present invention; [0034]
  • FIG. 14 is a schematic cross-sectional view of a human heart showing a conduit inserted by a percutaneous method into a channel created from the left ventricle to a coronary artery in accordance with the present invention; [0035]
  • FIG. 15 is a schematic cross-sectional view of a human heart showing a conduit inserted by a percutaneous method into a channel created from a coronary artery to the left ventricle in accordance with the present invention; [0036]
  • FIG. 16 is an integrated assembly to percutaneously perforate, dilate, and insert a conduit into a channel in the myocardium or other tissue layer in accordance with the present invention; [0037]
  • FIG. 17 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a percutaneous method into a channel created from a coronary artery to a coronary vein and into the left ventricle in accordance with the present invention; [0038]
  • FIG. 18 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a percutaneous method into a channel created from a coronary artery into a coronary vein distal to the channel into the left ventricle in accordance with the present invention; [0039]
  • FIG. 19 is a schematic cross-sectional view of a portion of the human heart showing a conduit inserted by a percutaneous method into a channel created from a coronary artery, both distal and proximal to a blockage, through a coronary vein and into the left ventricle in accordance with the present invention; [0040]
  • FIG. 20 is a cross sectional view of an embodiment of the valved conduit having projections as retaining means in accordance with the present invention; [0041]
  • FIG. 21 is a cross sectional view of another embodiment of the valved conduit having projections as retaining means in accordance with the present invention; [0042]
  • FIG. 22 is a cross sectional view of an embodiment of the valved conduit having a thread as retaining means in accordance with the present invention; [0043]
  • FIG. 23 is a cross sectional view of an embodiment of the valved conduit having a flared end as retaining means in accordance with the present invention; [0044]
  • FIG. 24 is a cross sectional view of an embodiment of the valved conduit having a coating as retaining means in accordance with the present invention; [0045]
  • FIG. 25 is a cross sectional view of an embodiment of the valved conduit having slots as retaining means in accordance with the present invention; [0046]
  • FIGS. 26A and 26B are cross sectional views of the myocardium changing thickness along a conduit during systole and diastole, respectively, in accordance with the present invention; [0047]
  • FIG. 27 is a cross sectional view of an embodiment of the valved conduit having telescoping sections as adjusting means in accordance with the present invention; [0048]
  • FIG. 28 is a cross sectional view of an embodiment of the valved conduit having telescoping sections as adjusting means in accordance with the present invention; [0049]
  • FIG. 29 is a cross sectional view of an embodiment of the valved conduit having an accordion section as adjusting means in accordance with the present invention; [0050]
  • FIG. 30 is a cross sectional view of an embodiment of the valved conduit having a lateral accordion section as adjusting means in accordance with the present invention; [0051]
  • FIG. 31 is a cross sectional view of an embodiment of the valved conduit having a coil as adjusting means in accordance with the present invention; [0052]
  • FIG. 32 is a side view of an embodiment of the conduit having a branch configuration in accordance with the present invention; [0053]
  • FIG. 33 is a side view of an embodiment of the conduit having a hook configuration in accordance with the present invention; [0054]
  • FIG. 34 is a side view of an embodiment of the conduit having a hybrid synthetic/natural configuration in accordance with the present invention; [0055]
  • FIG. 35 is a cross sectional view of a vein used as a valve in accordance with the present invention; [0056]
  • FIG. 36 is a cross sectional view of another embodiment of a vein used as a valve in accordance with the present invention; [0057]
  • FIG. 37 is a cross sectional view of a valve in accordance with the present invention; [0058]
  • FIG. 38A and FIG. 38B are side views of a conduit regulating blood flow during two phases of the heart cycle in accordance with the present invention; [0059]
  • FIG. 39 is a cross sectional view of a valve in a self-maintained channel in the myocardium in accordance with the present invention; [0060]
  • FIG. 40 is an isolated front view of the valve in FIG. 39; [0061]
  • FIG. 41 is a cross sectional view of a self-maintained channel in the myocardium in accordance with the present invention; and [0062]
  • FIG. 42 is a cross sectional view of a self-maintained channel in the myocardium in accordance with the present invention.[0063]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention generally describes a transmyocardial approach wherein one or more new channels, which are preferably about the size of a coronary artery, are formed between the left ventricle or other oxygenated blood source and one or more sites in the arterial vascular system of the heart selected for increasing the flow of blood thereto. Preferably, the selected site is in a position distal to one or more obstructed areas within the coronary circulation. The channel is created by penetrating completely through the tissue defining the blood source, such as the myocardium which defines the left ventricle, or the vascular tissue, which defines a coronary artery. The channel is maintained in an open state, by mechanical means or through tissue removal, in order for blood to flow through during the cycle of the heart. The channel is regulated or valved controlling both the direction and/or the quantity of blood flow through the channel between the left ventricle and the selected site in the arterial vascular system of the heart. [0064]
  • The present invention includes several methods for creating and maintaining a channel in the myocardium for the purposes of connecting an oxygenated blood source to the arterial vascular system of the heart, compromised by a coronary blockage. The inventive methods include both surgical and percutaneous approaches. Generally, the surgical approaches include direct access to the exterior of the patient's heart via a chest or thoracic approach. The percutaneous approaches include a minimally invasive technique using catheters or other devices which are inserted into the patients' vessels or heart at a remote access site and guided to the internal blockage site via visualization by instrumentation. The revascularization is then accomplished remotely. [0065]
  • As defined herein, the term diastole refers to the normal rhythmical relaxation of the heart chamber, especially the ventricles, during which they fill with blood. The term systole refers to the rhythmic contraction of the heart, especially the ventricles, during which blood is driven through the aorta and pulmonary artery after each diastolic period. The term distal is generally defined as in the direction of the patient, or away from a user of a device, or in a downstream direction relative to a forward flow of blood. In the context of a medical device intervention with or through a vascular tissue layer, distal herein refers to the interior or the lumen side of the vascular tissue layer or wall. Conversely, proximal generally means away from the patient, or toward the user, or in an upstream direction relative to a forward flow of blood. In the context of a medical device intervention with or through a vascular tissue layer, proximal herein refers to the exterior or outer side of the vascular tissue layer or wall. The term arterial vascular system of the heart includes, but is not limited to, the myocardium and coronary arteries. [0066]
  • Although the present invention is specifically described below with regard to the coronary artery, it should be understood that the present invention is not so limited and that the description is applicable to any part of the arterial vascular system of the heart. For example and not limitation, the description is applicable to the left anterior descending artery, the circumflex artery, the right coronary artery, and their tributaries. The description is also specific with regard to the left ventricle, but is applicable to other oxygenated blood sources of the arterial vascular system such as the left anterior descending artery, the circumflex artery, the right coronary artery, and their tributaries proximal to any obstruction or blockage. [0067]
  • A preferred method of the present invention is a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary [0068] vascular system 10 through the chest area using a needle assembly 12 as illustrated in FIGS. 1 and 2. Similar components between the figures herein are denoted by the same reference numerals. An initial access port 14 in the myocardium is made by advancing the needle assembly 12 through the myocardium 16 from the exterior side 18 of the myocardium 16 and into the left ventricle 20. Then a second access port 22 in the myocardium is made from the interior side 24 of the myocardium within the left ventricle 20 and underneath the coronary artery 26. The needle assembly 12 is advanced through the myocardium 16 from the left ventricle 20 and into the coronary artery 26 at a point distal to the lesion or blockage 28.
  • After the [0069] needle assembly 12 has created the second access port 22, a guide wire 30 or other directional means is extended from the distal end 32 of the needle assembly into the coronary artery 26. A sufficient length of the guide wire 30 is advanced into the coronary artery 26 to prevent its premature withdrawal. Optionally, the distal end 34 of the guide wire can contain a balloon 36 or other temporary anchoring means to prevent premature withdrawal of the guide wire 30 from the coronary artery. The proximal end 38 of the guide wire extends through the left ventricle 20 to the exterior 18 of the myocardium where it is available for manipulation by the surgeon. With the guide wire 30 extending from the exterior 18 of the myocardium, through the left ventricle 20 and into the coronary artery 26, the needle component 40 of the assembly is withdrawn from both the initial and second access ports.
  • The method uses the connection made by the [0070] second access port 22 between the left ventricle 20 and the coronary artery 26 to create and maintain a channel 42 therebetween. The initial access port 14 is dilated to allow the advancement of a delivery device 44 as illustrated in FIG. 3 having a sheath 46 covering a valved conduit 48. The sheath 46 is configured to assist the passage of the valved conduit 48 through the initial access port 14 without snagging the valved conduit 48 or damaging the myocardium 16. The delivery device 44 is advanced over the guide wire 30, through the initial access port 14, and into the left ventricle 20. The guide wire 30 directs the delivery device 44 to the second access port 22. The valved conduit 48 is then removed from the sheath 46 with a pusher rod 74 and the delivery device 44 inserts the valved conduit 48 into the second access port 22 so that the valved conduit 48 extends through the myocardium 16 from the left ventricle 20 to the coronary artery 26. The conduit 48 keeps the second access port 22 dilated and maintains the channel 42 between the left ventricle 20 and the coronary artery 26. The end 50 of the conduit preferably extends into the left ventricle 20 during the rhythmic contractions of the heart. It is preferred that the valved conduit end 50 extends into the left ventricle 20 at least during diastole when the myocardium is at the minimal thickness of its cycle. The other end 52 of the conduit can be approximately flush with the exterior 18 of the myocardium or extends slightly into the coronary artery 26 during at least during the diastole when the myocardium is at the minimal thickness of its cycle.
  • The remainder of the [0071] delivery device 44 is then withdrawn from the left ventricle 20 through the initial access port 14. Either simultaneous with or subsequent to the withdrawal of the delivery device 44, the balloon 36 at the distal end 34 of the guide wire is deflated (or the temporary anchor means is retracted) allowing withdrawal of the guide wire 30 from the coronary artery 26 along the valved conduit 48 and from the left ventricle 20 through the initial access port 14. The initial access port 14 is then sealed with a suture or allowed to seal itself without assistance.
  • Referring to FIG. 1, another embodiment of the present invention effectively anchors the [0072] distal end 34 guide wire by initially continuing to advance the guide wire beyond the coronary artery 26. As shown in phantom, the distal end 34A of the guide wire is advanced through the interior 70 and exiting from the exterior side 72 of the coronary artery. The distal end 34A is then exposed for anchoring in position.
  • The [0073] needle assembly 12 can be of any shape sufficient to perforate and penetrate the myocardium 16 while minimizing tissue damage. For example, FIG. 1 shows the needle assembly 12 having a curved shape which can assist in initially penetrating from the exterior side 18 of the myocardium and continuing to penetrate the interior side 24 of the myocardium underneath the coronary artery 26. Other shapes for the needle assembly 12 are suitable for use in the present invention which can penetrate and can depend upon the particular surgical approach to be used. For example and not limitation, FIG. 2 illustrates a straight needle assembly 12, commonly referred to as a seldinger-type needle. A suitable diameter for the needle component 40 is about 12 gauge.
  • FIG. 2 specifically illustrates more details of the [0074] needle assembly 12 other than an alternate shape. Preferably, the needle assembly 12 includes a needle component 40 having at least one lumen 54 extending substantially across length of the needle component. The first lumen 54 can be used to allow blood flow therethrough. As the distal end 32 of the needle assembly is advanced from the myocardium exterior 18 and enters the left ventricle 20, the blood in the left ventricle 20 will travel through the lumen 54 and blood 66 will be visually observed exiting the proximal end 62 of the needle assembly. This bleeding “flashback” 66 is especially prominent during the contraction of the left ventricle 20. As the distal end 32 of the needle assembly is further advanced through the left ventricle 20 to contact the myocardium interior 24, the bleeding flashback 66 will subside until the distal end 32 of the needle assembly completely penetrates the myocardium 16. The entry of the distal end 32 of the needle assembly into the coronary artery 26 will be evidenced by resumption of the bleeding flashback 66 through the proximal end 62 of the needle component or some other accessing feature. The first lumen 54 is also used to retractably carry the guide wire 30 therethrough.
  • Optionally, the [0075] assembly 12 can include a second lumen 56 which also extends substantially across the length of the needle component 40. One end 58A of the second lumen is located at the distal end 32 of the needle component. Alternately, the end 58B of the second lumen is located at some predetermined distance from the distal end 32 of the needle component. The other end 60 of the lumen is located near the proximal end 62 of the needle component. As the distal end 32 of the needle assembly is advanced from the myocardium exterior 18 and enters the left ventricle 20, the blood in the left ventricle 20 will travel from one end 58A or 58B of the second lumen to the other end 60 and blood 66 will be visually observed exiting the proximal end 62 of the needle assembly.
  • The [0076] lumen 54 or second lumen 56 and its ends 60 and 58A or 58B act as marker ports which provide evidence when the distal end 32 of the needle assembly is first in the left ventricle 20 and subsequently in the coronary artery 26. Other means for marking the position of the distal end 32 of the needle assembly are suitable for use with the present invention. For example and not limitation, the depth of the penetration through the myocardium to form the initial and second access ports 14 and 22 can be estimated by conventional diagnostic imaging and/or by reading one or more depth markers 68 placed in predetermined positions along the length of the needle assembly 12.
  • The [0077] needle assembly 12 provides for perforating the myocardium 16 to create and access port. The assembly 12 also provides for dilating the access port and for ensuring the position of the assembly has been advanced into the left ventricle 20 and/or coronary artery 26.
  • Another inventive method is a surgical approach which gains access to the exterior of the patient's heart illustrated in FIG. 4 through conventional cardiac surgical methods. Using the [0078] needle assembly 12 as previously described in FIG. 2, an initial access port 76 is made in the coronary artery 26 distal to the point of the obstruction 28. The needle assembly 12 is advanced into and through the coronary artery 26 to contact the exterior 18 of the myocardium underneath the coronary artery 26. The needle assembly 12 is further advanced to penetrate the myocardium 16 and make an access port 78 in the myocardium while eventually entering the left ventricle 20. The needle assembly 14 extends into the left ventricle 20 to the extent that flashback bleeding 66 is observed to assure the myocardium 16 has been completely penetrated.
  • After the [0079] needle assembly 12 has created the second access port 22, a guide wire 30 or other directional means is extended from the distal end 32 of the needle assembly into the left ventricle 20. A sufficient length of the guide wire 30 is advanced into the left ventricle 20 to prevent its premature withdrawal. Optionally, the distal end 34 of the guide wire can contain an inflatable balloon 36 or other temporary anchoring means to prevent premature withdrawal of the guide wire 30 from the left ventricle 20. With the guide wire 30 extending from the left ventricle 20 to the exterior 18 of the myocardium underneath the coronary artery 26, through the interior 70 of the coronary artery and to the exterior 72 of the coronary artery, the needle component 40 of the assembly is withdrawn from both the access ports 78, 76.
  • In another embodiment of this surgical approach wherein the [0080] initial access port 76 is created in the exterior of the coronary artery 26, it may be desirable to offset the alignment of the initial access port shown as 76A from the myocardium access port 78. This can be accomplished in several ways such as through simple angling of the needle assembly 12 while creating the access ports or using a needle assembly 12 which is curved or has an offset in its configuration. The eventual closing of the initial access port 76 may cause trauma to the vascular tissue in that area. Providing an offset in the alignment of the access ports 76A, 78 avoids the initial access port area from being directly over or along the path of the blood flow path from the inserted valved conduit 48.
  • Similar to what has been discussed before, the [0081] access port 78 in the myocardium is dilated to accommodate the delivery of a valved conduit 48 therein. Inserting the valved conduit 48 into the access port 78 creates and maintains by mechanical means a channel 42 through the myocardium from the left ventricle 20 to the coronary artery 26. The delivery of the valved conduit 48 can be effectuated by inserting a guide wire 30, withdrawing the needle assembly 12, directing a delivery assembly 44 as seen in FIG. 3 containing the valved conduit 48 over the guide wire 30 through the initial access port 76 to the access port 78, dilating the access port 78, inserting the valved conduit 48 into the access port 78, and withdrawing the delivery assembly 44 and guide wire 30 from the left ventricle 20 and coronary artery 26. Subsequently, the initial access port 76 on the exterior 72 of the coronary artery is closed by stitches, staples, or other closure means.
  • An alternate embodiment of the present invention employs a needle assembly and delivery assembly which are integrated so that the guide wire is eliminated. The integrated assembly provides sufficient dilation of the respective access ports to deliver the valved conduit therein. For example, as illustrated in FIG. 5, an [0082] integrated assembly 80 includes a perforating distal end 82 with a series of gradations or steps 84 for gradually dilating the respective access port as the integrated assembly 80 is further advanced. The steps 84 can be pre-formed or result from a retractable telescoping of the body 86 of the integrated assembly which can gradually vary its diameter. The valved conduit 48 is then removed from the body 86 with a pusher rod 88 and the integrated assembly 80 inserts the valved conduit 48 into the access port 78 so that the valved conduit 48 extends through the myocardium 16 from the left ventricle 20 to the coronary artery 26. The conduit 48 keeps the access port 78 dilated and maintains the channel 42 between the left ventricle 20 and the coronary artery 26.
  • Still another inventive method is a surgical approach which gains access to the exterior of the patient's heart and coronary [0083] vascular system 10 illustrated in FIG. 6 through conventional cardiac surgical methods. Using a first integrated needle/delivery assembly 90, an access port 92 is created through the myocardium 16 from the exterior side 18 into the left ventricle 20. Similar to the previous description herein, the distal end 98 of the integrated needle assembly perforates the myocardium and the myocardium access port 92 is dilated to accommodate the delivery of one end 96 of the valved conduit 94 which is advanced into the myocardium access port 92. Inserting the end 96 of the valved conduit into the myocardium access port 92 creates and maintains a channel through the myocardium 16 from the left ventricle 20 into one end 96 of the valved conduit.
  • Using a second needle/[0084] delivery assembly 100, an artery access port 102 is made in the exterior side 72 of the coronary artery. With surgical access to the artery access point 102, the second integrated needle/assembly 100 can immediately dilate the artery access port 102 and insert the other end 104 of the valved conduit after the integrated needle/delivery 100 perforates the coronary artery 26. Inserting the other end 104 of the valved conduit into the artery access port 102 creates and maintains a channel 42 from the left ventricle 20 into one end 96 of the valved conduit, out the other end 104 of the valved conduit, and into the coronary artery 26.
  • The first needle/[0085] delivery assembly 90 is more specifically illustrated in FIG. 7 which includes a body 106 made of a flexible material. The body 106 is perforated along its longitudinal axis to form seams 108. The valved conduit 94 extends along the longitudinal axis of the body 106 with the end 96 of the valved conduit positioned near the distal end 98 of the assembly and the other end 104 of the valved conduit exiting from the proximal end 110 of the assembly. Once the assembly 90 has perforated and dilated the myocardium access port 92, gripping the other end 104 of the valved conduit exiting from the assembly 90 can be helpful in either advancing the end 96 of the valved conduit into the myocardium access port 92 or holding the end 96 of the valved conduit within the myocardium access port 92 as the remainder of the assembly 90 is withdrawn. To ease the withdrawal of the assembly 90 from the myocardium access port 92, the perforations are broken apart to split the seams 108 and the longitudinal sections 112 and 114 of the body 106 are peeled away leaving the end 96 of the valved conduit in the myocardium access port 92.
  • In one alternate embodiment of the type of valved conduit that can be used with this surgical approach, the [0086] valved conduit 94 can have two separate conduit sections wherein a first conduit section 118 is inserted in the myocardium access port 92 and a second conduit section 119 is inserted in the artery access port 102. Subsequently, the two sections are connected together to form a continuous channel for the blood flow from the left ventricle 20 to the coronary artery 26. The valve 116 can be integrally positioned in either the first or second conduit section. Or, the valve 116 can be a separate piece from the two conduit sections wherein each conduit section connects to opposite sides of the valve.
  • In another embodiment of this surgical approach, delivery of either end [0087] 96 or 104, or both ends, of the valved conduit 94 can be effectuated by inserting a guide wire through a needle assembly as illustrated in FIG. 2 into the left ventricle 20, withdrawing the needle assembly, directing a delivery assembly as illustrated in FIG. 3 containing the valved conduit 94 over the guide wire to the myocardium access port 92, dilating the myocardium access port 92, inserting one end 96 of the valved conduit into the myocardium access port 92, and withdrawing the delivery assembly and guide wire from the left ventricle 20.
  • A further inventive method is a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary vascular system illustrated in FIG. 8. Using a first needle/[0088] delivery assembly 120 of similar design to the one illustrated in FIG. 7, a myocardium access port 122 is made in the myocardium 16 from the exterior side 18 into the left ventricle 20. The myocardium access port 122 is dilated to accommodate the delivery of a first input end 124 of a Y-shaped, multi-branched valved conduit 126 therein. Inserting the first input end 124 of the valved conduit into the myocardium access port 122 creates and maintains a channel 148 through the myocardium 16 from the left ventricle 20 into a first input end 124 of the conduit.
  • Using a second needle/[0089] delivery assembly 128, a distal artery access port 130 is made in the exterior side 72 of the coronary artery at a point distal to the lesion or blockage 28. With surgical access to the distal artery access port 130, the second assembly 128 can immediately dilate the distal artery access port 130 and insert an output end 132 of the multi-branched conduit after the second assembly 128 perforates the coronary artery 26.
  • Using a third needle/[0090] delivery assembly 134, a proximal artery access port 136 is made in the exterior side 72 of the coronary artery at a point proximal to the obstruction or blockage 28. With the surgical access to the proximal artery access point 136, the third assembly 134 can immediately dilate the proximal artery access port 136 and inserts a second input end 138 of the multi-branched conduit after the third assembly 134 perforates the coronary artery 26. Inserting the first input end 124 of the multi-branched conduit into the myocardium access port 122 and the second input end 138 of the multi-branched conduit into proximal artery access port 136 creates and maintains two channels 140 and 142 from two different blood sources, namely the left ventricle 20 and the coronary artery 26 proximal to the blockage 28, into the output end 132 of the multi-branched conduit and into the coronary artery distal to the blockage 28.
  • Preferably, a multi-branch, [0091] valved conduit 126 is used having at least two branches 140 and 142 with valving means 144 located in branch 140. With access afforded by this surgical approach, the two input ends 124 and 138 and output end 132 of the valved conduit each can be inserted similar to the previous description of FIGS. 6 and 7 without the assistance of remote guidance which avoids using a guide wire or the like through the interior of the conduit.
  • In an alternate embodiment of this surgical approach, each [0092] branch 140 and 142 of the conduit can initially be a separate component which can be connected together after the two input ends and output end have been inserted into the myocardium and the coronary artery proximal and distal to the blockage. The valving means 144 minimizing blood flow into the left ventricle is located in the branch 140 leading from the myocardium 16 between the first input end 124 and the connection to the second input end 138 and the output end 132. Alternately, the valving means 144 can be located near the distal artery port 130 as shown in phantom as 148. Optionally, a second valving means 146 for minimizing blood flow into the proximal coronary artery can be located in branch 142 leading from the proximal coronary artery between the second input end 138 and the connection between the first input end 124 and the output end 132. A second valving means 146 is particular useful if there is a valving means located near the distal artery port 130.
  • It should be understood that portions of different approaches can be combined. For example, a portion of the surgical approach described in FIG. 8 can be used to connect the proximal and distal [0093] coronary artery 26 with a channel like branch 142 external to the heart. Instead of providing another external channel like branch 140 to connect the left ventricle 20 with the distal coronary artery 26, a surgical approach as described in FIGS. 1 or 4 can provide an internal channel like 42 (FIGS. 1 or 4) positioned through the myocardium 20. As a result, blood flow from the left ventricle 20 arrives to the distal coronary 26 by an internal channel like 42 and from the proximal coronary artery through external channel like 142.
  • FIG. 9 illustrates another embodiment of a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary [0094] vascular system 10 for the placement of a valved conduit 150 through an extended portion along, or at an obtuse angle through, the myocardium 16 rather than taking the shortest path roughly perpendicularly through the myocardium. Using a first needle/delivery assembly 154, proximal artery access port 156 is made on the exterior side 72 of the coronary artery. The assembly 154 is advanced through the interior 70 of the coronary artery and along the myocardium before eventually creating an access port 160 to the left ventricle 20 through the myocardium 16. The proximal artery access port 156 and left ventricle access port 160 are dilated to accommodate the delivery of one branch 162 of the valved conduit 150 so that the valved conduit 150 is positioned at least partially along the myocardium and is preferably subjected to the movement created by the rhythmic contractions of the beating heart.
  • Using a second needle/[0095] delivery assembly 166, a distal artery access port 168 is created through the coronary artery 26 at a point distal to the lesion or blockage 28 into the exterior side 18 of the myocardium to connect with or near the left ventricle access port 160. The second assembly 166 can immediately dilate the distal artery access port 168 and insert the other branch 164 of the valved conduit into the coronary artery 26. As a result, the valved conduit 150 has two branches 162, 164 which traverse the myocardium 16 at an obtuse angle. The valved conduit 150 exhibits a substantially greater length compared to perpendicularly traversing the myocardium between the left ventricle 20 and coronary artery 26.
  • Although the [0096] valved conduit 150 can have a solid, rigid design, it is preferred in this embodiment to advantageously use the movement created by the rhythmic contractions of the beating heart to provide the regulation of the blood flow from the left ventricle 20 to the coronary artery 26 distal to the blockage 28. Accordingly, it is preferred that a substantial length the valved conduit 150 be made of a flexible material which allows the walls 152 of the valved conduit to flex with the rhythmic contractions of the beating heart and assist in the regulation of blood flow. The flexing of the conduit walls 152 can occur in several ways such as compression of its diameter or the lateral collapse of the conduit walls 152 upon themselves. It may be desirable to provide rigidity to the conduit walls 152 in the area of the valve 158 located near the access port 160 to preserve the integrity of the blood flow regulation by the conduit. It should be noted that the branches do not have to be connected and terminate at one access port 160. A second access port to the left ventricle is also suitable, so that each branch 162, 164 has a separate access port to the left ventricle 20.
  • Alternately, it is suitable to remove the [0097] valve 158 as a distinct component of the conduit by allowing the conduit walls 152 to flex by collapsing opposing walls against each other to provide the appropriate degree of closure during diastole. It may also be desirable to provide for regulating blood through both branches by locating the valve 158 only in branch 162. Examples of the proper alignment of the valved conduit 150 traversing the myocardium 16 are described in more detail below.
  • Other means of positioning the [0098] valved conduit 150 along a more extensive path between the left ventricle 20 and coronary artery 26 are suitable for use in the present invention. For example and not limitation, the direct access to the exterior of the heart 10 allows a trough to be excised between the left ventricle access port 160 and the distal artery access port 168. The left ventricle access port 160 can be created at one end of the trough and the distal artery access port 168 at the other end of the trough. One end of the valved conduit 150 is then positioned into the left ventricle and extends within the trough to the other end of the valved conduit which is inserted into coronary artery 26 as previously described therein.
  • Although the position of the [0099] valved conduit 150 is specifically illustrated as traversing the myocardium along an extended path or obtuse angle, it should be noted that the present invention is not so limited. The valved conduit 150 can be positioned partially or wholly within the myocardium including other tissue layers enveloping the heart i.e. pericardium, epicardium, endocardium, etc., or external to the heart and vascular system, or in a combination thereof.
  • Another embodiment of the surgical approach using the valved conduit at least partially positioned within the myocardium is to utilize a valved conduit with only one branch similar to the methods illustrated in FIGS. 1, 4 and [0100] 6. Optionally, other branches are added to the valved conduit 150 of FIG. 9 to connect to other sources of oxygenated blood, namely another coronary artery, or to deliver the oxygenated blood to multiple ischemic areas. Each additional branch can be positioned across the myocardium along an extended path or obtuse angle as described above or in a perpendicular direction across the myocardium.
  • FIG. 10 illustrates another embodiment of a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary [0101] vascular system 10 for the placement of a valved conduit 180 across the myocardium 16. A needle/delivery assembly 182 creates an initial access port 184 in the exterior side 72 of the coronary artery distal to the blockage 28. The assembly 182 is advanced through the interior 70 of the coronary artery to create an access port 190 through the vascular wall 186 of an adjacent coronary vein 188. The assembly 182 is then advanced through the coronary vein 188 to create an access port 192 in the exterior side 18 of the myocardium and completely through the myocardium 16 into the left ventricle 20. The valved conduit 180 is then inserted into and through the myocardium 16 creating a channel 42 directly from the left ventricle 20 to the coronary vein 188. The blood flow into the coronary vein 188 is limited to a particular area or section 170 by inserting plugs 194 within the coronary vein proximal and distal to the access ports 190, 192. The plugs 194 can be moved into their respective positions by insertion through the access ports 184, 190. Another technique for inserting the plugs 194 is to perforate, dilate, and insert the plugs 194 directly through the exterior side of the coronary vein 188 near the area the plugs 194 are desired. Devices or techniques other than plugs 194 can be used to isolate a section of the coronary vein 188 such as by using a suture around the vein in a position at least proximal to the access ports 190, 192 to close off blood flow to the section.
  • A [0102] second conduit 196 is inserted into the access port 190 to maintain a second channel 198 between the coronary artery 26 and the coronary vein 188. As a result, blood flows during systole from the left ventricle 20 into the coronary vein 188 and subsequently into the coronary artery 26 distal to the blockage 28. The coronary vein 188 can provide a temporary reservoir of blood. The valved conduit 180 minimizes backflow of blood from the coronary vein and artery during diastole. Upon withdrawal of the assembly 182, the initial access port 184 is closed.
  • As illustrated, the [0103] conduit 180 can optionally include a reservoir connected to it for temporarily storing blood. The reservoir may be a separate container like the section 170 of the coronary vein 188 that is connected to the conduit 180 or a container that is integrally formed with the surface of the conduit. The reservoir can also be effectively formed from a material which has the ability to expand and contract so that it becomes a reservoir during certain periods of the heart cycle.
  • The [0104] assembly 182 can be elongated to initially contain both the valved conduit 180 and the second conduit 196 so that each may be respectively positioned without withdrawing the needle assembly from the initial access port 184. Other alternates are available, such as withdrawing the needle assembly 182 to reload with the conduit not first placed in position. Or, temporarily dilating the access port 184 with another device so that a second needle/delivery assembly can be inserted through the same access port.
  • Although there is only one [0105] valved conduit 180 and it is positioned completely through the myocardium 16, the present invention includes several other options for regulating blood flow. For example, one option is to position the valved conduit 180 between the coronary artery 26 and coronary vein 188 and position the second conduit 196 without a valve through the myocardium between the left ventricle 20 and the coronary vein 188. This arrangement creates a reservoir of blood within the coronary vein 188 which may allow for blood flow into the coronary artery 26 during diastole.
  • Another option positions the [0106] valved conduit 180 and second conduit 196 as illustrated in FIG. 10. However, a valve shown in phantom as 180A is added to the second conduit 196. As a result, the coronary vein 188 provides a reservoir of blood in section 170 which augments blood flow into the coronary artery 26 during diastole. Another embodiment of this surgical approach wherein the channel between the left ventricle and coronary artery is transvascular and transmyocardial as illustrated in FIG. 11. An initial access port 184A is created in the top exterior of the coronary vein 188 instead of the coronary artery 26. The assembly 182 is advanced to create the access port 190 into the coronary artery 26, to insert the second conduit 196 and is then withdrawn. The assembly is also advanced from the initial access port 184A to create the access port 192 into the myocardium 16, insert the valved conduit 180 and is then withdrawn.
  • Alternately, the [0107] initial access port 184A is created to advance the assembly 182 and create an access port from the coronary vein 188 to either the left ventricle 20 through the myocardium 16 or to the coronary artery 26, but not both. Another initial access port 184B is created with the same or another assembly to complete the remaining access port. For example, access port 192 is made through the myocardium and the alternate access port 184B is used to make alternative access port 190B into the coronary artery 26. As a result, the alignment of the access ports 190B, 192 is offset from one another.
  • Although a [0108] valved conduit 180 is specifically illustrated in FIGS. 10 and 11, the coronary vein 188 itself can be used to regulate the flow of blood from the left ventricle 20 into the coronary artery 26. In this embodiment, the conduits 180 and 196 need not be valved, but simply maintain the respective channels. As discussed in more detail below, the natural valving function of vascular tissue in the isolated section of the coronary vein 188 can be advantageously used to regulate the flow of blood.
  • The present invention includes still another surgical approach wherein transvascular and transmyocardial channels between the left ventricle and coronary artery extend to more than one blood source as illustrated in FIG. 12. An additional [0109] initial access port 174A is created in the top exterior of the coronary vein 188 at a position which is proximal to the blockage 28 in the adjacent coronary artery 26. The assembly 182 is advanced through the interior of the coronary vein 188 to create an additional access port 172 for a third channel 178 through the exterior wall 72 of an adjacent coronary artery. A third conduit 176 is inserted into the additional second access port 172 to maintain the channel 178. One of the plugs 194 is inserted into the coronary vein 188 in a proximal position to the additional initial access port 174A.
  • Alternately, the additional [0110] initial access port 174B is created in the top exterior of the coronary artery proximal to the blockage 28. The assembly 182 is then advanced through the interior of the coronary artery to create the third channel 178 through the exterior wall 186 of an adjacent coronary vein.
  • Another method of the present invention is a surgical approach which directly accesses and exposes the outside of the patient's heart and coronary [0111] vascular system 10 through the chest area as illustrated in FIG. 13. As described herein, a needle delivery assembly can be used to perforate and dilate an access port 200 in the exterior side 18 of the myocardium so as to insert a valved conduit 204, preferably having a horizontal branch 208 to form a T-shape, into the left ventricle 20. The valved conduit 204 is positioned so that the branch 208 lies within the myocardium and the end 210 of the valved conduit extends within the left ventricle 20. The branch 208 is positioned to lie parallel to the myocardium 16. The valve 212 in the conduit is preferably positioned near the end 210. After insertion of the valved conduit 204, the exterior side 18 of the myocardium is closed by suturing or other suitable closure means.
  • Alternately, an incision can be made along a suitable course in the [0112] exterior side 18 of the myocardium such as along the phrenic nerve into the vascular area of myocardium 16 above the left ventricle 20 in front of the coronary artery. The incision is deepened almost to the interior side 24 of the myocardium or the endocardium 202. Optionally, a small cavity 206 can be created to assist in the placement of the conduit 204. As previously described, a needle assembly is then used to perforate through the endocardium 202 or remaining myocardium below the incision 200, to the left ventricle 20.
  • An example of suitable dimensions for the preferred T-shaped [0113] valved conduit 204 is about a 4 mm diameter with a vertical branch 214 of about 15 mm and the horizontal branch 208 of about 20 mm long. The horizontal branch 208 is provided to divert blood flow into a direction parallel to the myocardium 16 layer. Other designs for the valved conduit 204 are suitable for use in the present invention. For example and not limitation, the valved conduit 204 can be a straight stem or have a two horizontal branches in a cross shape. The valved conduit 204 can be made of a porous material that allows blood flow to emanate from the entire length, or selected portions, of the vertical branch 214 and/or horizontal branch 208.
  • Another preferred method of the present invention is a percutaneous approach which generally introduces a catheter or other guidance/delivery device into the blood source such as the left ventricle. A [0114] catheter 220 is placed into the circulatory system 10 at a remote access site such as the femoral artery and advanced through the aortic valve into the left ventricle 20 as illustrated in FIG. 14. The catheter 220 then is directed to the interior side 24 of the myocardium 16 underneath the coronary artery 26 where a penetrating or perforating needle 222 is delivered and advanced from the left ventricle 20 through the myocardium 16 into the coronary artery 26 to create an access port 224 therethrough.
  • Once the [0115] catheter 222 has been guided to the desired location, the perforating needle 222 is exchanged for a valved conduit 226 which is delivered to the access port 224 and inserted into the myocardium 16. As described above, the valved conduit 226 extends completely through the myocardium 16 to create and maintain a channel 42 between the left vertical 20 and the coronary artery 26 distal to the blockage 28.
  • There are several conventional techniques for locating the position of a [0116] catheter 222 in various places in the human body. For example and not limitation, the locating means can be an ultrasound system, magnetic resonance imaging, computer aided tomography or an echocardiograph. A fluid or medium such as a dye can be introduced by conventional means into the left ventricle 20 that allows its identification by a scanning instrument and provides a background to identify the location of the guided catheter 222 in relation to the coronary artery 26 and the left ventricle 20.
  • A suitable inventive method using the percutaneous approach is illustrated in FIGS. 15 and 16. A [0117] catheter 228 and guide wire 238 are inserted into the coronary artery 26 from a remote access site such as along the femoral artery. The guide wire 238 is used to cross the blockage 28 and then the catheter 228 is inserted over the guide wire and advanced past the blockage. The catheter 228 includes a body 230 having a distal end 232 and proximal end 234 with a window 236. A guide wire 238 assists in guiding the catheter 228 into the desired position and exchanging a perforating needle 244 and a valved conduit as discussed above. The window 236 is rotated for proper orientation so that the window 236 faces the tissue layer of the coronary artery 26 against the exterior side 18 of the myocardium wherein an access port 248 is to be created. Optionally, the body 230 includes a balloon 240 which can retractably expand against the inner tissue wall of the coronary artery 26 to hold the window 236 in its proper orientation.
  • The [0118] body 230 includes a ramp 242 which directs the perforating needle 244 on a wire into the tissue layer to create the access port 248. Preferably, the wire 238 has a hole in its center to provide for back bleeding as means of evidencing the position of the needle 244. Alternately, the scanning instrument can determine the position of the needle 244 advancement. Subsequently, the ramp 242 directs the insertion of the valved conduit 250 into the created access port.
  • Another embodiment of the present invention combines portions of different percutaneous approaches. As described in FIG. 15, a [0119] guide wire 238 is inserted into the coronary artery 26 from a remote access site such as along the femoral artery. The guide wire 238 is used to cross the blockage 28 and is advanced into the left ventricle 20. Using the path described in FIG. 14, a guide wire is advanced from the same access site into the left ventricle and is used to snare the guide wire 238 advanced from the coronary artery and retrieve the guide wire 238 back to the remote access site. As a result, the guide wire 238 completes a circuit from the remote access site through the coronary artery, across the myocardium, to the left ventricle and back to the remote access site. One or more devices can then be advanced through the left ventricle to the interior side of the myocardium without crossing the blockage in the coronary artery.
  • Another inventive method using the percutaneous approach which advances a [0120] catheter 260 into the coronary artery 26 from a remote access site such as along the femoral artery is illustrated in FIG. 17. Once the position of the catheter 260 is determined within the coronary artery 26, a penetrating wire 262 is advanced from the catheter to go from the coronary artery and penetrate into an adjacent coronary vein 264. An excess amount of the penetrating wire 262 is advanced into the coronary vein 264 to assist in retaining the penetrating wire within the coronary vein as the catheter is similarly advanced from the coronary artery 26 into the coronary vein 264. The position of the catheter 260 is then determined in the coronary vein 264 relative to the left ventricle 20. The catheter 260 is directed to orient the perforating wire 262 towards the myocardium 16 underneath the coronary vein 264 and to the left ventricle 20.
  • The [0121] perforating wire 262 creates an initial access port 268 through the vascular wall 272 of the adjacent coronary vein 264 and a second access port 270 in the exterior side 18 of the myocardium and completely through the myocardium 16 into the left ventricle 20. A valved conduit 266 is then inserted into and through the myocardium 16 creating a channel 42 directly from the left ventricle 20 to the coronary vein 264. The blood flow into the coronary vein 264 is limited to a particular area or section 286 by inserting plugs 274 within the coronary vein on both sides of the initial and second access ports 268, 270. The plugs 274 can be moved into their respective positions by insertion through the initial access port 268.
  • A [0122] second conduit 276 is inserted into the initial access port 268 to maintain a second channel 278 between the coronary artery 26 and the coronary vein 264. As a result, blood flows during systole from the left ventricle 20 into the coronary vein 264 and subsequently into the coronary artery 26 distal to the blockage 28. The coronary vein 264 can provide a temporary reservoir of blood. The valved conduit 266 minimizes backflow of blood from the coronary vein 264 and artery 26 into the left ventricle 20 during diastole.
  • Another embodiment of this method is illustrated in FIG. 18. The [0123] initial access port 268 is offset in its alignment with the second access port 270A. The catheter 260 is guided to a location either a distance further distal or proximal to the initial access port 268 before the second access port 270A is created. FIG. 18 specifically illustrates a distal position.
  • The present invention includes still another percutaneous approach wherein transvascular and transmyocardial channels between the left ventricle and coronary artery extend to more than one blood source as illustrated in FIG. 19. An [0124] additional access port 280 is created between the coronary artery and the adjacent vein 264 proximal to the blockage 28 in the adjacent coronary artery 26. The catheter 260 is advanced through the interior of the coronary vein 264 to create the access ports 268 and 270. A third conduit 282 is inserted into the additional access port 280 to maintain the third channel 284. One of the plugs 274 is inserted into the coronary vein 264 in a proximal position to the additional access port 280.
  • It should be understood that the present invention provides for combining portions of different surgical approaches, different percutaneous approaches, or a combination of surgical and percutaneous approaches in one method. For example, a surgical approach can use a catheter in a method similar to that described with reference to FIGS. [0125] 14-19. After gaining access to the exterior of the patient's heart and coronary vascular system, the same access area is used to guide the catheter to the coronary vascular system at a location which is significantly closer to the heart.
  • The present invention provides alternate methods of creating the access ports for the surgical and percutaneous approaches described above. Instead of dilating the access ports, a section of tissue can be removed to provide the channel through the myocardium or the vascular tissue. The diameter of the tissue section to be removed is preferably about equivalent to or larger than the diameter of the valved conduit to be inserted. [0126]
  • For example and not limitation, a section of tissue can be removed by mechanical means such as by positioning a rotary drill head or punch at the [0127] distal end 32 of the needle assembly in FIG. 2 or the distal end of the delivery device 44 in FIG. 3. As the result, the dilation of the access port is partially or completely obviated.
  • Another suitable means for removing tissue is laser energy which is commonly used in transmyocardial revascularization (TMR) techniques with adjustments to make a larger diameter channel than is conventionally used in TMR. A laser can be used with either the surgical or percutaneous approaches described herein. The surgical approaches provide adequate space to align the laser from a position external to the heart and vascular system or the laser can be introduced into the left ventricle or coronary system and create a channel from the inside extending outward. A laser fiber can be carried by a guided catheter as described in the methods above. [0128]
  • The tissue removal means of the present invention provides channels which are self-maintaining. Channels created by the removal of tissue can avoid the use of a conduit to keep or maintain the channel open. As defined herein, the term self-maintained channel is a passageway through tissue which is open for blood flow from an oxygenated blood source to a selected site during at least a portion of the heart cycle, preferably during systole. With a self-maintaining channel, the regulation of blood is controlled by inserting only a valve, no conduit, into the channel. Or, the self-maintained channel can regulate the flow of blood naturally by orienting the self-maintained channel through the myocardium as described herein. [0129]
  • The conduits and valves of the present invention are made of natural vascular tissue or synthetic materials or a combination of both. The synthetic materials are bio-compatible and include metals, alloys and plastics containing one or more polymers. The conventional surgical polymers are suitable plastics. Metals or alloys which are not in themselves bio-compatible can be coated with a bio-compatible metal or plastic. Preferably, the conduit material is non-porous to blood. However, it is suitable to use material porous to blood and still provide blood flow completely through the length of the conduit. [0130]
  • A preferred [0131] synthetic conduit 400 is illustrated in FIG. 20 having an elongated body 402 with a cylindrical or tubular shape and a wall 404 having an exterior surface 406 and an interior surface 408. The wall 404 defines an interior space 410. The body 402 includes an inlet end 412 for receiving blood from the left ventricle or other oxygenated blood source and an outlet end 414 for delivering the oxygenated blood to a selected site such as a coronary artery or vein.
  • The preferred shape of the cross-section of the [0132] body 402 along its longitudinal axis 416 is circular. Other cross-sectional shapes are suitable for use by the present invention such as, for example and not limitation, triangular, rectangular, square, elliptical, oval, and other geometric or free-form shapes. The cross-sectional size is illustrated as uniform across the length of the body 402. However, the cross-sectional size can vary along the length of the body 402, or taper or flare the body 402 near the ends 412 and 414.
  • The diameter of the [0133] conduit 400 is preferably not expandable and is inserted into the channel 42 as a predetermined size without the need to expand the diameter of the body 402. The body 402 resists compressive forces placed on it by the myocardium during the heart cycle to maintain the channel 42 in the open position. However, the present invention also provides for using conduits with a diameter which is expandable after insertion into the myocardium.
  • Preferably, the length of the [0134] conduit 400 is sized to be longer than the maximum width the myocardium achieves during the heart cycle. The conduit 400 extends beyond the exterior side 18 and interior side 24 defining the myocardium and slightly into the left ventricle 20 and coronary artery 26. It is suitable to provide the length of the conduit 400 so that one end is approximately flush with the interior side 24 and/or exterior side 18 of the myocardium.
  • The [0135] conduit 400 includes projections 418 integrally formed with the body 402 near the inlet end 412 and outlet 414 means for retaining the conduit in position once it has been inserted within the myocardium 16 or other tissue layer. The projections 418 can have an end 420 which is barbed or otherwise shaped for slightly penetrating, embedding, or abutting the myocardium 16 in the area surrounding the ends 412 and 414. The connection between the body 402 and the projections 418 includes a spring bias which allows the projections 418 to fold relatively flat against the exterior surface 406 of the body while the conduit 400 is being inserted into the channel 42 through the myocardium 16 or tissue layer. The projections 418 then relax to their outwardly extended position once the ends 412, 414 of the conduit extend into the left ventricle 20 and coronary artery 26 and are clear of the channel 42. For example, the spring bias can be supplied by conventional memory or superelastic materials.
  • Preferably, the [0136] synthetic conduit 400 includes a valve 422 having flaps 424 which open to allow blood flow in one direction from the left ventricle 20 to the coronary artery 26 and close to minimize the backflow of blood in the reverse direction. The closure of the flaps 424 need not completely seal the interior space 410. The valve 422 can be supported by a ring 426 inserted within the interior space 410 so as to abut the interior surface 408 as a component separate from the body 402. Alternately, the valve 422 can be integrally formed with the wall 404.
  • Other examples of retaining means are provided by the present invention. For example and not limitation, FIG. 21 illustrates [0137] projections 430 which are initially retracted into the interior space 410 through slots 432 in the wall 404. The connection between the body 402 and the projections 430 includes a spring bias which allows the projections 430 to retract into the interior space 410 of the body while the conduit 400 is being inserted into the channel 42 through the myocardium 16 or tissue layer. The projections 430 then released to their outwardly extended position once the conduit 400 is in the desired position. This embodiment also illustrates that the projections 430 slightly penetrate the face 434 of the channel 42 rather the area of the myocardium surrounding the channel.
  • Another example of the retaining means provided by the present invention include forming a [0138] screw thread 436 on the exterior surface 406 of the body as illustrated in FIG. 22. The thread 436 is of sufficient size and quantity to hold the conduit 400 in the desired position by biting into the face 434 of the channel. The thread 436 can extend over one or more sections of the exterior surface 406. The thread 436 need not be continuous and can be positioned anywhere along the length of the exterior surface 406.
  • Other examples of the retaining means provided by the present invention includes expanding one or both ends of the [0139] conduit 400 to a diameter greater than the channel 42. FIG. 23 illustrates the inlet end 412 being flared 438 so that its diameter is greater than the diameter of the channel 42. The flared end 438 extends beyond the myocardium 16 layer. The end 438 can be flared prior to or after insertion of the conduit 400 into desired position. FIG. 24 illustrates the inlet end 412 being effectively expanded by a coating 440 applied to the exterior surface 406 of the conduit near the end. The coating 440 expands after insertion 440A to hold the conduit 400 in the desired position. There are several known plastics or foams which exhibit predictable expansion properties which are suitable material for use as the coating 440.
  • In similar embodiments, an adherence between the [0140] exterior surface 406 of the conduit and the face of the myocardium along the channel can be promoted to retain the conduit in the desired position. For example, at least a portion of the length of the conduit 400 can be coated on the exterior surface 406 with a bio-compatible adhesive which assists the adherence with the face of the myocardium. Another example is to abrade the exterior surface 406 of the conduit.
  • FIG. 25 illustrates that the retaining or anchoring means can be located anywhere along the length of the [0141] body 482 of the conduit 480 such as the middle section 484. Another type of anchoring means is also illustrated in the form of elongated slots 486. By having comparable sizes in the diameters of the conduit 480 and the channel, the face of the myocardium along the channel may embed into the areas of the slots 486 to retain the conduit in the desired position.
  • The retaining means can also be useful in sizing the length of a conduit immediately after insertion through the myocardium. For example, using the surgical approach described in reference to FIG. 4, a conduit having a length significantly longer that the myocardium's maximum width can be inserted through the coronary artery and into the myocardium. Preferably, the end of the conduit extending into the left ventricle includes a retaining means. Once the resistance of the retaining means is felt by attempting to withdraw the conduit, the excess length of the conduit extending out of the myocardium and through the coronary artery is cut off. [0142]
  • The [0143] conduit 400 with valve 422 of the present invention preferably adjusts to the changing width of the myocardium 16 during the heart cycle. FIGS. 26A and 26B illustrate another example of the conduit 400 provided by the present invention wherein the inlet end 412 is flared 438 and the outlet end 414 have projections 442 which slightly penetrate into the area of the myocardium 16 surrounding the channel 42. During systole, the thickness of the myocardium 16 is near its greatest during the heart cycle. As illustrated in FIG. 26A, the outlet end 414 of the conduit extends slightly into the coronary artery 26 and is retained in positioned by being anchored to the exterior side 18 of the myocardium. The length of the conduit 400 is predetermined so that the inlet end 412 of the conduit also extends slightly into the left ventricle 20 when the myocardium 16 is thickest during the heart cycle. Optionally, the inlet end 412 can be flared 438 so as to further assure retaining the interior side 24 of the myocardium to provide at least a slight extension of the inlet end 412 into the left ventricle 20. During diastole, the thickness of the myocardium 16 decreases. As illustrated in 26B, the outlet end 414 is anchored on one side of the conduit allowing the remainder of the myocardium to slide along the longitudinal axis 416 of the conduit. The inlet end 412 is not specifically anchored and is free to extend further into the left ventricle 20 during diastole.
  • The present invention provides other means for adjusting the [0144] conduit 400 to the changing width of the myocardium 16 during the heart cycle. FIG. 27 illustrates the conduit 400 with at least a two telescoping components 444, 446 which slidably insert into one another as indicated by arrow 445. Both the inlet end 412 and the outlet end 414 retain the myocardium in the desired position by anchoring the ends with projections 442 to the interior side 24 and exterior side 18 of the myocardium, respectively. As the heart cycles, the component 446 slides within component 444 in a telescoping manner to adjust to the changing thickness of the myocardium. The length of the telescoping components 444, 446 are predetermined so that they remain within each other all through the heart cycle.
  • Other examples of means for adjusting the [0145] conduit 400 to the changing width of the myocardium 16 during the heart cycle include the illustration in FIG. 28 which provides the conduit 400 with an accordion section 456 which expands and contracts in a longitudinal direction as indicated by arrow 457 while providing resistance against radial compression. Each end 412 and 414 retain the myocardium in the desired position by anchoring the ends with projections 442 to the interior side 24 and exterior side 18 of the myocardium, respectively. As the heart cycles as indicated by arrow 452, the two ends 412, 414 move towards each other during diastole and away from each other during systole with the accordion section 456 respectively contracting and expanding in a longitudinal direction.
  • Alternately, FIG. 29 illustrates another [0146] accordion section 458 which reversibly expands in a latitudinal direction. Each end 412 and 414 retain the myocardium in the desired position by anchoring the ends with projections 442 to the interior side 24 and exterior side 18 of the myocardium, respectively. As the heart cycles, the two ends 412, 414 move towards each other during diastole and away from each other during systole with the accordion section 458 respectively contracting and expanding in a latitudinal direction as indicated by arrows 460. The latitudinal accordion section 458 not only maintains and regulates blood flow through the channel, but also provides a temporary reservoir of blood in the accordion section 458 itself. The valve 422 can be placed at either end 412, 414 or valves placed at both.
  • Another example of the adjusting means of the present invention is illustrated in FIG. 30 wherein the [0147] conduit 400 includes at least two components 448, 450 which form a body 402 which is discontinuous. Each end 412 and 414 retains the myocardium 16 in the desired position by anchoring the ends with projections 442 to the interior side 24 and exterior side 18 of the myocardium, respectively. The valve 422 can be included in either component 488 or 450. With the components 448, 450 positioned perpendicular to the myocardium width, the two components 448, 450 move towards each other during diastole and away from each other during systole when the heart cycles as indicated by arrow 452. Without support from either component 448, 459, a section 454 of the channel between the-two components 448, 450 is self-maintained in the open position.
  • FIG. 31 illustrates an example of an adjusting means wherein the [0148] conduit 400 includes a body 402 made of a continuous coil 462 which expands and contracts along its longitudinal axis to accommodate the changing thickness of the myocardium 16 during the heart cycle while resisting radial compression. The outer periphery 464 of the coil 462 slides along the face 466 of the myocardium defining the channel 42. The coil 464 is anchored to the myocardium 16 at the inlet end 468 and outlet end 470 by projections 472 which are supported by rings 474 connecting to respective ends of the coil 464. As the coil 462 expands, gaps 476 are formed between the outer periphery 464 of individual spirals or the gaps 476 increase in size if the gaps already exist when the coil 462 is at its maximum level of relaxation during systole. Should the face 466 of the myocardium adhere to the outer periphery 464 of one or more individual spirals, either immediately after insertion into the channel or as a long-term effect, the remaining spirals provide expansion by moving along the longitudinal axis.
  • The present invention provides conduits with a variety of configurations emphasizing a non-obtrusive, non-traumatic connection into the coronary artery. As illustrated in FIG. 32, a T-shaped [0149] conduit 490 includes a branch 492 allowing the continued flow of blood or prevents the stasis of blood proximal to the conduit in the coronary artery 26. FIG. 33 illustrates a hook-shaped conduit 494 having a right-angle bend toward the direction of desired blood flow. The outer periphery 496 of the conduit outlet end can be sized to have the coronary artery dilated over its edge or can be smaller than the diameter of the coronary artery. FIG. 34 illustrates a hybrid, synthetic/natural conduit 497 which includes a section of vascular tissue 498 attached to a synthetic segment 499. The vascular tissue 498 is attached 495 to the wall 493 of the coronary artery by conventional closure means such as suturing. In this embodiment, no section of the conduit 497 extends into the coronary artery.
  • The present invention also provides a naturally valved conduit such as a vein or other vascular tissue which is preferably autologous. A conduit made from the vein can be all natural or include synthetic materials in combination with the vein. As illustrated in FIG. 35, a [0150] preferred combination conduit 500 combines a vein 502 which is at least partially supported by a synthetic cage 504 having an elongated body 506 with a cylindrical or tubular shape and longitudinal members 508 having an exterior surface 510 and an interior surface 512. The cage 504 defines an interior space 514. The body 506 includes end members 516 connected to the longitudinal members 508. The cage 504 includes projections 518 which, as previously described, retain the conduit 500 in the desired position with the myocardium.
  • The [0151] vein 502 is extended along the interior surface 512 through the interior space 514 of the conduit. The ends 520 of the vein 502 are stretched over end members 516 and back in the reverse direction to secure the vein 502 to the cage 504. Optionally, a suture can be placed through the end 520 and the wall 528 of the vein. The vein 502 defines an inlet end 522 for receiving blood from the left ventricle or other oxygenated blood source and an outlet end 524 for delivering the oxygenated blood to a selected site such as a coronary artery or vein.
  • The present invention regulates the flow of blood through the [0152] conduit 500 utilizing the flaps and wall movement of the vein which are inherent, natural properties of the vein 502. The natural valving function of the vein 502 is preserved by allowing the wall 528 of the vein to move towards itself or substantially collapse upon itself as indicated by arrows 526.
  • Another embodiment of the [0153] combination conduit 500 is illustrated in FIG. 36. The cage 504 includes a second pair of end members 530 spaced in a parallel relationship to the end members 516 and connected to the longitudinal members 508. Each end 520 of the vein 502 is inserted in a press fit between one of the end members 516 and second end members 530 to secure the vein 502 to the cage 504. Other means of securing the vein 502 to the cage 504 are also suitable such as be suturing the ends 520 of the vein to the end members 516 with a continuous suture or a plurality of individual sutures. FIG. 36 also illustrates another example of positioning the vein 502 along the exterior side 510 of the cage. As indicated in phantom 528A, the wall 528 moves toward itself or substantially collapses upon itself to preserve the natural valving of the vein 502.
  • The present invention provides other types of valves for regulating the flow of blood through a conduit or a self-maintained channel. One valve type, as used in the Examples herein, is similar to a Starling resistor and illustrated in FIG. 37. The [0154] conduit 550 includes a rigid, elongated body 552 having an inlet end 554 which extends into the left ventricle 20. The body 552 extends substantially through the myocardium 16. On the outlet end 556 of the body is attached a valve 558 having a tubular body 560 made of a pliable material which extends into the coronary artery 26 distal to the blockage 28. The pliable material can be a section of vein. The tubular body 560 is sufficiently flexible to collapse on itself. During systole, blood flows out of the outlet end 556 into the coronary artery. As the cycle of the heart approaches diastole, the pressure of the blood flowing from the outlet end 556 decreases to the point where the pliable body 560 collapses which minimizes the reverse flow of blood from the coronary artery 26 back into the left ventricle 20. Optionally, a cage 548 can be inserted into the coronary artery 26 in the area of the tubular body 560 to assist in preventing the collapse of the artery in that area.
  • Another example of the valves provided by the present invention is illustrated in FIGS. 38A and 38B. A [0155] conduit 560 extends completely through the myocardium 16 and slightly into the left ventricle 20 and the coronary artery 26. The conduit 560 includes at least one segment 562 that is made of a pliable material which resists compression by small radial forces but which collapses as seen in FIG. 38B during a portion of the heart cycle. The conduit 560 is orientated at an obtuse angle to the interior side 24 and exterior side 18 of the myocardium and to the direction of change in the thickness of the myocardium. Because of the conduit's 560 orientation within the myocardium 16, the forces applied by the surrounding myocardium as it contracts and relaxes during the cycle of the heart change the both the length and diameter of the conduit 560 as generally illustrated in FIG. 38B. As a result, the flow of blood is minimized into the left ventricle 20 during the cycle of the heart.
  • As described above, the present invention provides a self-maintained [0156] channel 600 defined by a face 602 of the myocardium 16 as illustrated in FIG. 39. The channel 600 extends completely through the myocardium 16 in a perpendicular direction from the left ventricle 20 on the interior side 24 to the coronary artery 26 on the exterior side 18. The channel 600 is created by removing tissue so that it remains at least partially open during the cycle of the heart.
  • Preferably, the self-maintained [0157] channel 600 includes a valve 604 inserted within the channel as illustrated in FIGS. 39 and 40. The valve 604 includes interleaved flaps 606 supported on a body 608. The valve 604 is not associated with a conduit. The width of the body 608 is preferably the minimum size required to provide support and orientation for the flaps 606 and not particularly to maintain the channel 600 open. The flaps 606 are set to open during positive pressure exerted by blood flow in the direction from the left ventricle 20 to the coronary artery 26. Negative pressure or blood flow in the reverse direction at least partially closes the flaps 606 to minimize the flow of blood to the left ventricle 20.
  • The [0158] body 608 includes a periphery 610 having a thread 612 integrally formed along the periphery. The thread 612 includes a starting edge 614 for engaging the face 602 and slightly dilating the diameter of the myocardium 16. As the periphery 610 is rotated, the starting edge 614 assists the advance of the thread 612 into contact with the face 602 of the myocardium. The thread 612 can slightly embed itself or slightly penetrate into the face 602 of the myocardium to retain the valve 604 in the self-maintained channel 600.
  • Another example of a mechanical means for regulating blood flow is to use a material in place of the [0159] flaps 606 which is semi-permeable to blood flow. The semi-permeable material can allow the blood to flow from the left ventricle while minimizing the reverse flow of blood.
  • The present invention also provides self-maintained channels which regulate the flow of blood without a synthetic valve as illustrated by the examples in FIGS. 41 and 42. Self-maintained [0160] channel 620 extends completely through the myocardium 16 from the left ventricle 20 to the coronary artery 26. The channel 620 includes two segments 622 and 624 which are orientated at an obtuse angle to the interior side 24 and exterior side 18 of the myocardium, respectively. A third segment 626 connects to the other segments 622, 624 and is orientated in a generally parallel direction relative to the sides 24, 18 of the myocardium and-a perpendicular direction to the change in the thickness of the myocardium. Because the orientation within the myocardium of the two segments 622, 624 and third segment 626 are different, each of the segments is affected differently by forces applied by the surrounding myocardium as it contracts and relaxes during the cycle of the heart. The forces from the myocardium can change both the length and diameter of the segments 622, 624, and 626. As a result, the flow of blood is minimized into the left ventricle 20 during the cycle of the heart. It should be noted that arrows indicate only a general movement of the myocardium 16 in changing thickness during the heart cycle. There are forces experienced during the heart cycle within the myocardium 16 which are not strictly orientated perpendicular to the coronary artery and left ventricle.
  • Another example of a self-maintained channel which regulates the flow of blood therethrough with the natural rhythmic cycle of the heart is illustrated in FIG. 42. The self-maintained [0161] channel 640 includes a bowed or curved configuration which extends completely through the myocardium 16 from the left ventricle 20 to the coronary artery 26. With proper orientation of the bowed configuration between the interior side 24 and exterior side 18 of the myocardium, the forces applied by the surrounding myocardium as it contracts and relaxes during the cycle of the heart can be advantageously used to regulate the flow of blood through the channel 640. The forces from the myocardium can change both the length and diameter of the channel 640. As a result, the flow of blood is minimized into the left ventricle 20 during the cycle of the heart.
  • EXAMPLES
  • Two sets of experiments utilizing animals were designed to evaluate the acute functionality of the inventive methods. Each experiment was performed on a beating heart. No type of temporary assist or heart-lung bypass technique was utilized. Anesthesia was maintained with oxygen administration in accordance with conventional protocol. ECG was monitored and an arterial monitoring catheter was placed in the left internal mammary artery for assessment of blood pressure. [0162]
  • The first set of experiments was carried out on seven female Yorkshire pigs weighing 30-35 kg. On four of the pigs, a formal sternotomy was used and in the other three pigs, a left anterior 4[0163] th intercostal space thoracotomy was used. A prototype conduit was introduced into the left ventricle through a formal sternotomy with the other end of the conduit introduced into the left anterior descending coronary artery through cannualation. The left anterior descending coronary artery was then tied proximally. In this set of experiments, blood flow was delivered to the proximally occluded left anterior descending artery from the left ventricular chamber through a valved conduit, there being no other blood supply to the left anterior descending coronary artery.
  • Several different types of inventive valves were incorporated within the conduit. These valves consisted of a fine penrose tube or an IMA vein suspended between two ports in a chamber which could be pressurized. The IMA vein would be harvested shortly before and have about a 2 cm length with one or two valves. When connected in this fashion, blood passed in a continuous path from the left ventricular chamber via the penrose tube or vein into the left anterior descending coronary artery. The surrounding chamber could then be pressurized to any pre-determined level and in this way, the penrose tube or vein would collapse and prevent backflow when left ventricular pressure fell below the pressurized chamber level. The penrose tube or vein functioned in a manner commonly referred to as a “Starling resister” similar to that illustrated in FIG. 20. [0164]
  • Another valve type employed a small penrose tube or a vein segment Which was suspended from only one port in a non-pressurized chamber with a second opening in the chamber allowing continuity of blood flow from the left ventricle to the left anterior descending artery. Each harvested vein graft was inserted between the two catheters, creating a valved conduit approximately 15 mm long with an overall length of about 10 cm for complete external pathway. In this embodiment, any attempt at backflow of blood to the left ventricular chamber would cause collapse of the penrose tube or vein segment and occlude the backflow port. [0165]
  • In the seven pigs, Doppler flow measurement revealed both systolic and some diastolic flow in the left anterior descending coronary artery. Blood flow was confirmed by miniature Doppler on the distal coronary and vein graft and the flow pattern was about systolic (80%), diastolic (20%). There was no obvious demarcation of an ischemic zone distal to the left anterior descending coronary artery ligation nor were arrhythmias or an observable decrease in left ventricular contraction noted. The inventive conduit was left in place from 30 min. to 1 and ½ hours. [0166]
  • With occlusion of the conduit carrying blood from the left ventricular chamber, all of the hearts fibrillated within 3-5 minutes. This result indicated that the ventricular supply of coronary blood was essential and provided for normal function for the duration of the experiment. [0167]
  • The second set of experiments were designed to evaluate the net coronary flow per minute whether delivered in systole or diastole, under control conditions and compared these to the net coronary flow in mL/min delivered from the left ventricle as the only source (all proximal coronary arteries having been ligated.) In this set of experiments six Yorkshire pigs weighing 30-35 kg underwent surgical stemotomy and cannulation of the coronary sinus—the common outflow of all coronary blood flow. The left hemiazygous vein was ligated so that coronary sinus blood was not contaminated by the systemic circulation. Under control conditions all blood flow emanating from the coronary sinus was collected for a specific period of time and the mL of coronary blood flow per minute calculated. A left ventricular conduit was then surgically inserted into the left ventricular chamber from the epicardial surface and then connected to cannulas which had been inserted into the left and right coronary os. When the left main coronary artery and the right coronary artery were snared around the introduced cannula the left ventricle was the only source for coronary blood flow. In this experimental set-up, coronary blood flow therefore originated from the left ventricle and passed through a prototype conduit and valving system as described above into the right coronary os and left coronary os. Measurement of total coronary blood flow emanating from the coronary sinus under this condition demonstrated no difference in net coronary blood flow per minute from the control condition. With the coronary artery ligated, net coronary blood flow per minute originating from the left ventricular chamber via the inventive conduit was also measured without a valve in place. These sets of experiments demonstrated that net coronary blood flow per minute was similar whether delivered via the aortic root under control conditions or from a left ventricular source via the inventive conduit. [0168]
  • Several clinical discoveries were made which further support the physiologic viability of the inventive methods. There is a similarity of physiology to patients with Aortic Valve Insufficiency. The delivery requirements per beat are very small. Continuous flow is observed during coronary angiograms. The mean pressure within the myocardium is relatively low compared to systolic perfusion pressure. The animals experienced no change in EKG and no change in heart wall motion. There was no change in flow characteristics of blood. The coronary arterial system was compliant and enabled diastolic perfusion. [0169]
  • Some conclusions may be drawn from other observations. The dynamic motion of heart muscle and subsequent motion of the conduit may reduce stasis which contributes to clot formation. The high velocity of delivery from the left ventricle to the coronary artery may reduce incidence of clot formation and resulting thrombosis (occlusion). The short length of the conduit (approximately 15 mm) may reduce the chance of clot formation and thrombosis (occlusion). [0170]
  • In comparing the inventive left ventricle to coronary artery approach to the conventional coronary perfusion approach, it was found that the same amount of blood was being delivered across the myocardium to the coronary sinus in both approaches. Compared to conventional transmyocardial revasculation techniques the present invention used much larger holes, enabled patency of the channel and demonstrated the heart's ability to tolerate this type of intervention with little effect. [0171]
  • The present invention provides significant advantages when compared to the prior art relating to interventional procedures such as the ability to improve long term patency rates and reduce the high rate of retreatment. Furthermore, the present invention allows multiple vessels to be treated. Compared to CABG surgery, the present invention is a less-invasive procedure which can be performed on a beating heart using smaller incisions for entry than normally required by conventional techniques. Also, harvesting an autologous graft may not be needed. [0172]
  • The present invention fulfills many needs found wanting in the prior art. Many patients were not candidates for percutaneous or CABG surgery because they could not be fully revascularized by the surgery. The present invention significantly enlarges the population of potential candidates. Furthermore, the use of small ports between the ribs to provide the revascularization provides an access site in the immediate vicinity of the selected site in the arterial vascular system and avoids the use of a sternotomy and/or a thoracotomy. The present invention provides access to the arterial vascular system on both sides of the heart such as the left anterior descending artery, circumflex artery, and as well as their tributaries. [0173]
  • As described, the present invention fulfills many clinical needs that are currently unmet by the prior art. For example, many patients with coronary artery disease are not amenable to CABG or percutaneous treatment due to their extensive disease. However, this invention offers a comparable treatment alternative to conventional techniques allowing these patients to receive care. Furthermore, the inventive approach provides for methods and devices that allow for coronary revascularization procedures to be performed through small holes instead of a chest incision. The present invention provides access to the arterial vascular system allowing for all vessels of the heart to be revascularized. [0174]
  • The present invention also provides for partial revascularization or increased flow by having a self-maintained channel or conduit without a valve. In this embodiment, a channel is created and maintained between an oxygenated blood source and a site selected in the arterial vascular system. The channel does not incorporate means for regulating the blood flow therethrough. More particularly, when the selected site is distal to a substantial or complete blockage or occlusion, a self-maintained channel or conduit without a valve between the left ventricle and selected site provides significant, but not complete, revascularization of the selected site and the surrounding area. [0175]

Claims (38)

What is claimed is:
1. A method for increasing the flow of blood to a selected site in a patient's arterial vascular system of the heart, the method comprising the steps of:
creating a channel for blood flow from an oxygenated blood source to the selected site in the arterial vascular system of the heart;
maintaining the channel in an open position for blood flow through diastolic and systolic cycles of the heart; and
regulating the blood flow in the channel to minimize blood flow from the coronary vascular system to the blood source during diastole.
2. The method of
claim 1
wherein the creating step includes perforating and dilating the tissue surrounding the blood source to create the channel therein.
3. The method of
claim 1
wherein the creating step includes removing tissue to form an aperture completely through the tissue surrounding the blood source to partially create the channel therein.
4. The method of
claim 1
wherein the creating step includes exposing at least a portion of the patient's heart for surgical access.
5. The method of
claim 1
wherein the creating step includes advancing a delivery device to the tissue surrounding the blood source.
6. The method of
claim 1
wherein the blood source is the left ventricle and the tissue surrounding the blood source is the myocardium.
7. The method of
claim 1
wherein the method includes more than one blood source.
8. The method of
claim 1
wherein the method includes more than one site in the arterial vascular system.
9. The method of
claim 1
wherein the method includes selecting a site in the arterial vascular system distal to an obstruction therein.
10. A method for performing a transmyocardial coronary revascularization procedure for the treatment of coronary atherosclerosis caused by an obstruction in the arterial vascular system, the method comprising the steps of:
creating a channel for blood flow from an oxygenated blood source to the arterial vascular system distal to the area of obstruction;
maintaining the channel in an open position for blood flow through the diastole and systole cycles of the heart; and
regulating the blood flow in the channel to minimize blood flow from the arterial vascular system to the blood source during the diastolic cycle of the heart.
11. The method of
claim 10
wherein the creating step includes perforating and dilating the tissue surrounding the blood source to create the channel therein.
12. The method of
claim 10
wherein the creating step includes removing tissue to form an aperture completely through the tissue surrounding the blood source to partially create the channel therein.
13. The method of
claim 10
wherein the creating step includes exposing at least a portion of the patient's heart for surgical access.
14. The method of
claim 10
wherein the creating step includes advancing a delivery device to the tissue surrounding the blood source.
15. The method of
claim 10
wherein the blood source is the left ventricle and the tissue surrounding the blood source is the myocardium.
16. The method of
claim 10
wherein the method includes more than one blood source.
17. The method of
claim 10
wherein the method includes more than one site in the arterial vascular system.
18. The method of
claim 10
wherein the method includes selecting a site in the arterial vascular system distal to an obstruction therein.
19. A method for treating an obstruction in a patient's cardiovascular system using a non-expandable conduit made of biocompatible material, the method comprising the steps of:
inserting the conduit completely through the myocardium of the patient's heart with one end of the conduit extending into the left ventricle and the other end of the conduit extending into the arterial vascular system distal to the area of obstruction;
maintaining the conduit in an open position for blood flow through the diastolic and systolic cycles of the heart;
regulating the blood flow in the channel to minimize blood flow from the arterial vascular system to the left ventricle during the diastolic cycle of the heart.
20. The method of
claim 19
wherein the inserting step includes perforating and dilating the tissue surrounding the blood source to create the channel therein.
21. The method of
claim 19
wherein the inserting step includes removing tissue to form an aperture completely through the tissue surrounding the blood source to partially create the channel therein.
22. The method of
claim 19
wherein the inserting step includes exposing at least a portion of the patient's heart for surgical access.
23. The method of
claim 19
wherein the inserting step includes advancing a delivery device to the tissue surrounding the blood source.
24. The method of
claim 19
wherein the blood source is the left ventricle and the tissue surrounding the blood source is the myocardium.
25. The method of
claim 19
wherein the method includes more than one blood source.
26. The method of
claim 19
wherein the method includes more than one site in the arterial vascular system.
27. The method of
claim 19
wherein the method includes selecting a site in the arterial vascular system distal to an obstruction therein.
28. A method for increasing the flow of blood to a selected site in a patient's arterial vascular system, the method comprising the steps of:
inserting one end of a conduit into the left ventricle;
inserting the second end of the conduit into the arterial vascular system at the selected site;
maintaining the conduit in an open position for blood flow through the diastolic and systolic cycles of the heart;
regulating the blood flow in the conduit to minimize blood flow from the arterial vascular system to the left ventricle during the systolic cycle of the heart.
29. The method of
claim 28
wherein the method includes connecting the ends of the conduit together.
30. The method of
claim 28
wherein the method includes:
accessing the patient's myocardium; and
perforating the myocardium.
31. The method of
claim 28
wherein the inserting step includes perforating and dilating the tissue surrounding the blood source to create the channel therein.
32. The method of
claim 28
wherein the inserting step includes removing tissue to form an aperture completely through the tissue surrounding the blood source to partially create the channel therein.
33. The method of
claim 28
wherein the inserting step includes exposing at least a portion of the patient's heart for surgical access.
34. The method of
claim 28
wherein the inserting step includes advancing a delivery device to the tissue surrounding the blood source.
35. The method of
claim 28
wherein the blood source is the left ventricle and the tissue surrounding the blood source is the myocardium.
36. The method of
claim 28
wherein the method includes more than one blood source.
37. The method of
claim 28
wherein the method includes more than one site in the arterial vascular system.
38. The method of
claim 28
wherein the method includes selecting a site in the arterial vascular system distal to an obstruction therein.
US09/833,921 1998-02-13 2001-04-11 Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart Abandoned US20010025643A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/833,921 US20010025643A1 (en) 1998-02-13 2001-04-11 Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2349298A 1998-02-13 1998-02-13
US09/833,921 US20010025643A1 (en) 1998-02-13 2001-04-11 Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US2349298A Continuation 1998-02-13 1998-02-13

Publications (1)

Publication Number Publication Date
US20010025643A1 true US20010025643A1 (en) 2001-10-04

Family

ID=21815415

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/833,921 Abandoned US20010025643A1 (en) 1998-02-13 2001-04-11 Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart
US10/011,630 Expired - Fee Related US7137962B2 (en) 1998-02-13 2001-10-22 Devices and methods for use in performing transmyocardial coronary bypass
US11/594,464 Abandoned US20070055344A1 (en) 1998-02-13 2006-11-08 Devices and methods for use in performing transmyocardial coronary bypass

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/011,630 Expired - Fee Related US7137962B2 (en) 1998-02-13 2001-10-22 Devices and methods for use in performing transmyocardial coronary bypass
US11/594,464 Abandoned US20070055344A1 (en) 1998-02-13 2006-11-08 Devices and methods for use in performing transmyocardial coronary bypass

Country Status (6)

Country Link
US (3) US20010025643A1 (en)
EP (1) EP1054641A1 (en)
JP (1) JP2002502663A (en)
AU (1) AU755190B2 (en)
CA (1) CA2320956A1 (en)
WO (1) WO1999040868A1 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030325A3 (en) * 2000-10-11 2002-08-22 Heartstent Corp Flexible transmyocardial implant
WO2002030326A3 (en) * 2000-10-11 2002-09-06 Heartstent Corp Transmyocardial implant with anchor element
US20030055371A1 (en) * 1998-01-30 2003-03-20 Percardia, Inc. Left ventricular conduits to coronary arteries and methods for coronary bypass
US6582444B2 (en) 1999-08-04 2003-06-24 Percardia, Inc. Blood flow conduit delivery system and method of use
US6605113B2 (en) 1999-08-04 2003-08-12 Percardia Inc. Vascular graft bypass
US20030158573A1 (en) * 1998-02-13 2003-08-21 Ventrica, Inc Devices and methods for use in performing transmyocardial coronary bypass
US6610100B2 (en) 1998-09-10 2003-08-26 Percardia, Inc. Designs for left ventricular conduit
US6638237B1 (en) 1999-08-04 2003-10-28 Percardia, Inc. Left ventricular conduits and methods for delivery
US6641610B2 (en) 1998-09-10 2003-11-04 Percardia, Inc. Valve designs for left ventricular conduits
US6694983B2 (en) 1998-09-10 2004-02-24 Percardia, Inc. Delivery methods for left ventricular conduit
US20040077987A1 (en) * 1998-02-13 2004-04-22 Ventrica, Inc., Corporation Of Delaware Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication
WO2004073555A1 (en) * 2003-02-19 2004-09-02 Axel Haverich Methods and devices for improving cardiac output
US20050080476A1 (en) * 2003-10-09 2005-04-14 Gunderson Richard C. Medical device delivery system
US20070088375A1 (en) * 2004-03-23 2007-04-19 Correx, Inc. Apparatus and method for forming a hole in a hollow organ
US20070112422A1 (en) * 2005-11-16 2007-05-17 Mark Dehdashtian Transapical heart valve delivery system and method
US7704222B2 (en) 1998-09-10 2010-04-27 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US8226670B2 (en) 2004-03-23 2012-07-24 Correx, Inc. Apparatus and method for connecting a conduit to a hollow organ
US8277465B2 (en) 2004-12-15 2012-10-02 Correx, Inc. Apparatus and method for connecting a conduit to a hollow vessel
US8512360B2 (en) 1998-02-13 2013-08-20 Medtronic, Inc. Conduits for use in placing a target vessel in fluid communication with source of blood
US20130304111A1 (en) * 2012-05-11 2013-11-14 Michael Zhadkevich Anti-embolic device and method
US20160082231A1 (en) * 2009-01-29 2016-03-24 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US9381082B2 (en) 2011-04-22 2016-07-05 Edwards Lifesciences Corporation Devices, systems and methods for accurate positioning of a prosthetic valve
US9687345B2 (en) 2014-05-29 2017-06-27 Edwards Lifesciences Cardiaq Llc Prosthesis, delivery device and methods of use
US9737696B2 (en) 2014-01-15 2017-08-22 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US9808260B2 (en) 2014-05-04 2017-11-07 Zhadkevich Medical, Inc. Noninvasive protection from emboli
US10130374B2 (en) 2012-05-11 2018-11-20 Michael Zhadkevich Anti-embolic device and method
US10149757B2 (en) 2013-03-15 2018-12-11 Edwards Lifesciences Corporation System and method for transaortic delivery of a prosthetic heart valve
US10258348B2 (en) 2015-01-27 2019-04-16 Michael Zhadkevich Devices and techniques for vascular compression
US10857017B2 (en) * 2017-07-14 2020-12-08 Bcm Co., Ltd. Stent insertion device for connecting human digestive organs
WO2021025905A1 (en) * 2019-08-06 2021-02-11 Edwards Lifesciences Corporation External cardiac bypass shunting
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11103416B2 (en) 2015-09-28 2021-08-31 Michael Zhadkevich Device and method for simultaneous detection, monitoring and prevention of cerebral emboli
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
US11278708B2 (en) 2014-01-15 2022-03-22 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7027398B2 (en) * 2001-04-12 2006-04-11 General Instrument Corporation Method and apparatus for monitoring voice conversations from customer premises equipment
US6432126B1 (en) * 1998-09-30 2002-08-13 C.R. Bard, Inc. Flexible vascular inducing implants
US6458092B1 (en) * 1998-09-30 2002-10-01 C. R. Bard, Inc. Vascular inducing implants
US7578828B2 (en) * 1999-01-15 2009-08-25 Medtronic, Inc. Methods and devices for placing a conduit in fluid communication with a target vessel
US6475226B1 (en) 1999-02-03 2002-11-05 Scimed Life Systems, Inc. Percutaneous bypass apparatus and method
US6406491B1 (en) 1999-05-04 2002-06-18 Heartstent Corporation Compliant transmyocardial implant
CA2381192A1 (en) * 1999-08-04 2001-02-15 Percardia, Inc. Methods and apparatus for direct coronary revascularization
US20080018016A1 (en) * 1999-09-10 2008-01-24 Rapacki Alan R Manufacturing conduits for use in placing a target vessel in fluid communication with a source of blood
US6635214B2 (en) * 1999-09-10 2003-10-21 Ventrica, Inc. Manufacturing conduits for use in placing a target vessel in fluid communication with a source of blood
SE517410C2 (en) * 2000-09-20 2002-06-04 Jan Otto Solem Device and insertion device for providing a complementary blood flow to a coronary artery
US6602286B1 (en) * 2000-10-26 2003-08-05 Ernst Peter Strecker Implantable valve system
US6596024B2 (en) * 2000-12-21 2003-07-22 Carbomedics Inc. Polymeric heart valve fabricated from polyurethane/polysiliconeurethane blends
EP1395214B1 (en) * 2001-04-27 2014-02-26 Cormend Technologies, LLC Prevention of myocardial infarction induced ventricular expansion and remodeling
EP1592367B1 (en) * 2002-08-28 2016-04-13 HLT, Inc. Method and device for treating diseased valve
FR2846520B1 (en) * 2002-11-06 2006-09-29 Roquette Freres USE OF MALTODEXTRINS BRANCHED AS BLEACHES OF GRANULATION
IES20030531A2 (en) 2003-07-17 2005-09-21 Medtronic Vascular Connaught Methods and devices for placing a fistula device in fluid communication with a target vessel
IES20030539A2 (en) 2003-07-22 2005-05-18 Medtronic Vascular Connaught Stents and stent delivery system
US11207457B2 (en) * 2004-08-27 2021-12-28 Edwards Lifesciences Corporation Device and method for establishing an artificial arterio-venous fistula
GB0419954D0 (en) * 2004-09-08 2004-10-13 Advotek Medical Devices Ltd System for directing therapy
JP4855784B2 (en) * 2006-01-16 2012-01-18 日本コヴィディエン株式会社 Gripping tool
US7568753B2 (en) * 2006-06-15 2009-08-04 Mattel, Inc. Children's ride-on vehicles with reconfigured bodies and methods for forming the same
JP5616891B2 (en) 2008-08-26 2014-10-29 セント ジュード メディカル インコーポレイテッドSt. Jude Medical, Inc. Method and system for sealing a percutaneous puncture
WO2010123668A1 (en) * 2009-04-20 2010-10-28 Rox Medical, Inc. Device and method for establishing an artificial arterio-venous fistula
WO2013171276A1 (en) 2012-05-16 2013-11-21 Endovascular Development AB An assembly with a guide tube, a fixator for attaching to a blood vessel, and a pump
EP2908880B1 (en) 2012-10-16 2018-12-05 Paul A. Spence Devices for facilitating flow from the heart to a blood pump
US9545263B2 (en) 2014-06-19 2017-01-17 Limflow Gmbh Devices and methods for treating lower extremity vasculature
EP4299086A2 (en) 2017-04-10 2024-01-03 LimFlow GmbH Devices for treating lower extremity vasculature
CN108309504B (en) * 2018-02-27 2019-07-26 宁波迪创医疗科技有限公司 A kind of ventricular assist device enhancing heart function
WO2020076833A1 (en) 2018-10-09 2020-04-16 Limflow Gmbh Devices and methods for catheter alignment
JP7178247B2 (en) * 2018-12-03 2022-11-25 朝日インテック株式会社 Blood vessel model and organ simulator
JP2023500067A (en) 2019-11-01 2023-01-04 リムフロウ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Devices and methods for increasing blood perfusion to distal limbs
WO2023220119A1 (en) * 2022-05-10 2023-11-16 Abiomed, Inc. Distal limb perfusion cannula stent & stent cannula cover

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US603856A (en) * 1898-05-10 Soda-water fountain
US3316914A (en) * 1963-02-14 1967-05-02 Michael B Collito Surgical methods and devices for anastomosis
DE2513868C2 (en) * 1974-04-01 1982-11-04 Olympus Optical Co., Ltd., Tokyo Bipolar electrodiathermy forceps
US4368736A (en) * 1980-11-17 1983-01-18 Kaster Robert L Anastomotic fitting
US4902289A (en) * 1982-04-19 1990-02-20 Massachusetts Institute Of Technology Multilayer bioreplaceable blood vessel prosthesis
US4546499A (en) * 1982-12-13 1985-10-15 Possis Medical, Inc. Method of supplying blood to blood receiving vessels
US4581017B1 (en) * 1983-03-07 1994-05-17 Bard Inc C R Catheter systems
US4520808A (en) 1983-03-10 1985-06-04 Stauffer Chemical Company Inhalation exposure apparatus
US4523592A (en) * 1983-04-25 1985-06-18 Rollin K. Daniel P.S.C. Anastomotic coupling means capable of end-to-end and end-to-side anastomosis
US5275622A (en) * 1983-12-09 1994-01-04 Harrison Medical Technologies, Inc. Endovascular grafting apparatus, system and method and devices for use therewith
US4580568A (en) * 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US4728328A (en) * 1984-10-19 1988-03-01 Research Corporation Cuffed tubular organic prostheses
US5302336A (en) * 1987-04-16 1994-04-12 Metzeler Automotive Profiles Gmbh Method for producing molded hose branches from rubber and a hose produced by the method
US4822341A (en) * 1987-11-20 1989-04-18 Impra, Inc. Vascular access fistula
US4995857A (en) * 1989-04-07 1991-02-26 Arnold John R Left ventricular assist device and method for temporary and permanent procedures
US4985014A (en) * 1989-07-11 1991-01-15 Orejola Wilmo C Ventricular venting loop
US5571169A (en) * 1993-06-07 1996-11-05 Endovascular Instruments, Inc. Anti-stenotic method and product for occluded and partially occluded arteries
US4997431A (en) * 1989-08-30 1991-03-05 Angeion Corporation Catheter
US5360443A (en) * 1990-06-11 1994-11-01 Barone Hector D Aortic graft for repairing an abdominal aortic aneurysm
US5078735A (en) * 1990-06-18 1992-01-07 Mobin Uddin Kazi Prosthetic grafting method for bypass surgery
US5111832A (en) * 1990-07-24 1992-05-12 Sanjeev Saksena Processes for the control of tachyarrhythmias by in vivo laser ablation of human heart tissue
US5100423A (en) * 1990-08-21 1992-03-31 Medical Engineering & Development Institute, Inc. Ablation catheter
US5389096A (en) * 1990-12-18 1995-02-14 Advanced Cardiovascular Systems System and method for percutaneous myocardial revascularization
US5505725A (en) * 1990-10-30 1996-04-09 Cardiogenesis Corporation Shapeable optical fiber apparatus
US5380316A (en) * 1990-12-18 1995-01-10 Advanced Cardiovascular Systems, Inc. Method for intra-operative myocardial device revascularization
US5383925A (en) * 1992-09-14 1995-01-24 Meadox Medicals, Inc. Three-dimensional braided soft tissue prosthesis
CA2065634C (en) * 1991-04-11 1997-06-03 Alec A. Piplani Endovascular graft having bifurcation and apparatus and method for deploying the same
US5190058A (en) * 1991-05-22 1993-03-02 Medtronic, Inc. Method of using a temporary stent catheter
US5452733A (en) * 1993-02-22 1995-09-26 Stanford Surgical Technologies, Inc. Methods for performing thoracoscopic coronary artery bypass
FR2683449A1 (en) * 1991-11-08 1993-05-14 Cardon Alain ENDOPROTHESIS FOR TRANSLUMINAL IMPLANTATION.
US5211624A (en) * 1991-12-09 1993-05-18 Cinberg James Z Surgical closure device method
US5395349A (en) * 1991-12-13 1995-03-07 Endovascular Technologies, Inc. Dual valve reinforced sheath and method
US5209731A (en) * 1991-12-13 1993-05-11 Endovascular Technologies, Inc. Hand-held gun for inflating and aspirating large volume balloons
US5327913A (en) * 1992-03-25 1994-07-12 Taheri Syde A Percutaneus cardiomyoplasty method
US5758663A (en) * 1992-04-10 1998-06-02 Wilk; Peter J. Coronary artery by-pass method
US5494041A (en) * 1992-08-19 1996-02-27 Wilk; Peter J. Method for use in surgical operation
US5314436A (en) * 1992-10-30 1994-05-24 Wilk Peter J Method and apparatus for performing end-to-end anastomoses
US5429144A (en) * 1992-10-30 1995-07-04 Wilk; Peter J. Coronary artery by-pass method
US5409019A (en) * 1992-10-30 1995-04-25 Wilk; Peter J. Coronary artery by-pass method
US5287861A (en) 1992-10-30 1994-02-22 Wilk Peter J Coronary artery by-pass method and associated catheter
CA2102084A1 (en) * 1992-11-09 1994-05-10 Howard C. Topel Surgical cutting instrument for coring tissue affixed thereto
US5318527A (en) * 1992-12-22 1994-06-07 Advanced Cardiovascular Systems, Inc. Fixed wire catheter exchange device
US6494211B1 (en) * 1993-02-22 2002-12-17 Hearport, Inc. Device and methods for port-access multivessel coronary artery bypass surgery
US5425705A (en) * 1993-02-22 1995-06-20 Stanford Surgical Technologies, Inc. Thoracoscopic devices and methods for arresting the heart
US5425765A (en) * 1993-06-25 1995-06-20 Tiefenbrun; Jonathan Surgical bypass method
US5713950A (en) * 1993-11-01 1998-02-03 Cox; James L. Method of replacing heart valves using flexible tubes
US5497774A (en) * 1993-11-03 1996-03-12 Daig Corporation Guiding introducer for left atrium
WO1995013033A1 (en) * 1993-11-08 1995-05-18 Lazarus Harrison M Intraluminal vascular graft and method
US5503635A (en) * 1993-11-12 1996-04-02 United States Surgical Corporation Apparatus and method for performing compressional anastomoses
US5501698A (en) * 1994-02-14 1996-03-26 Heartport, Inc. Endoscopic microsurgical instruments and methods
US5397320A (en) * 1994-03-03 1995-03-14 Essig; Mitchell N. Dissecting surgical device and associated method
US5613069A (en) * 1994-12-16 1997-03-18 Tony Walker Non-blocking packet switching network with dynamic routing codes having incoming packets diverted and temporarily stored in processor inputs when network ouput is not available
US5591226A (en) * 1995-01-23 1997-01-07 Schneider (Usa) Inc. Percutaneous stent-graft and method for delivery thereof
US5904697A (en) * 1995-02-24 1999-05-18 Heartport, Inc. Devices and methods for performing a vascular anastomosis
US5888247A (en) * 1995-04-10 1999-03-30 Cardiothoracic Systems, Inc Method for coronary artery bypass
US5603722A (en) * 1995-06-06 1997-02-18 Quanam Medical Corporation Intravascular stent
US5620439A (en) * 1995-06-06 1997-04-15 George S. Abela Catheter and technique for endovascular myocardial revascularization
DE69633411T2 (en) 1995-10-13 2005-10-20 Transvascular, Inc., Menlo Park METHOD AND DEVICE FOR PREVENTING ARTERIAL ATTRACTIONS AND / OR FOR CARRYING OUT OTHER TRANSVASCULAR INTERVENTIONS
EP0955933B1 (en) * 1995-10-13 2009-08-26 Medtronic Vascular, Inc. A device for interstitial transvascular intervention
WO1997027898A1 (en) 1996-02-02 1997-08-07 Transvascular, Inc. Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures
AU733341B2 (en) 1996-02-02 2001-05-10 Transvascular, Inc. A device, system and method for interstitial transvascular intervention
JPH09215753A (en) * 1996-02-08 1997-08-19 Schneider Usa Inc Self-expanding stent made of titanium alloy
US5766220A (en) * 1996-02-29 1998-06-16 Moenning; Stephen P. Apparatus and method for protecting a port site opening in the wall of a body cavity
JP3336353B2 (en) 1996-04-08 2002-10-21 ザ、プロクター、エンド、ギャンブル、カンパニー Container with dropper and inner stopper
US5713949A (en) * 1996-08-06 1998-02-03 Jayaraman; Swaminathan Microporous covered stents and method of coating
SE509388C2 (en) * 1996-05-17 1999-01-18 Jan Otto Solem Branching device for a blood vessel
US6007544A (en) * 1996-06-14 1999-12-28 Beth Israel Deaconess Medical Center Catheter apparatus having an improved shape-memory alloy cuff and inflatable on-demand balloon for creating a bypass graft in-vivo
FR2750853B1 (en) * 1996-07-10 1998-12-18 Braun Celsa Sa MEDICAL PROSTHESIS, IN PARTICULAR FOR ANEVRISMS, WITH PERFECTIONED CONNECTION BETWEEN ITS SHEATH AND ITS STRUCTURE
SE509389C2 (en) * 1996-07-24 1999-01-18 Solem Jan Otto Device for connecting the end of a first blood vessel to the side of a second blood vessel
FR2751867B1 (en) * 1996-08-05 1999-05-21 Leriche Rene Ass PROSTHESIS COLLERETTE
US5755682A (en) * 1996-08-13 1998-05-26 Heartstent Corporation Method and apparatus for performing coronary artery bypass surgery
US5655548A (en) 1996-09-16 1997-08-12 Circulation, Inc. Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion
US5755778A (en) * 1996-10-16 1998-05-26 Nitinol Medical Technologies, Inc. Anastomosis device
US6019788A (en) * 1996-11-08 2000-02-01 Gore Enterprise Holdings, Inc. Vascular shunt graft and junction for same
US5875782A (en) * 1996-11-14 1999-03-02 Cardiothoracic Systems, Inc. Methods and devices for minimally invasive coronary artery revascularization on a beating heart without cardiopulmonary bypass
US5897587A (en) * 1996-12-03 1999-04-27 Atrium Medical Corporation Multi-stage prosthesis
US5879321A (en) * 1997-01-22 1999-03-09 The University Of Kentucky Research Foundation Portocaval-right atrial shunt
US5899934A (en) * 1997-01-31 1999-05-04 Medtronic, Inc Dual stent
US5893369A (en) * 1997-02-24 1999-04-13 Lemole; Gerald M. Procedure for bypassing an occlusion in a blood vessel
US5855597A (en) * 1997-05-07 1999-01-05 Iowa-India Investments Co. Limited Stent valve and stent graft for percutaneous surgery
US6056762A (en) * 1997-05-22 2000-05-02 Kensey Nash Corporation Anastomosis system and method of use
US6063114A (en) * 1997-09-04 2000-05-16 Kensey Nash Corporation Connector system for vessels, ducts, lumens or hollow organs and methods of use
US6017352A (en) * 1997-09-04 2000-01-25 Kensey Nash Corporation Systems for intravascular procedures and methods of use
US6250305B1 (en) * 1998-01-20 2001-06-26 Heartstent Corporation Method for using a flexible transmyocardial implant
US6214041B1 (en) * 1998-01-20 2001-04-10 Heartstent Corporation Transmyocardial implant with septal perfusion
US7027398B2 (en) 2001-04-12 2006-04-11 General Instrument Corporation Method and apparatus for monitoring voice conversations from customer premises equipment
US6352543B1 (en) * 2000-04-29 2002-03-05 Ventrica, Inc. Methods for forming anastomoses using magnetic force
US20010041902A1 (en) 1998-02-13 2001-11-15 Michael J. Lynch Anastomotic methods and devices for placing a target vessel in fluid communication with a source of blood
WO1999040868A1 (en) 1998-02-13 1999-08-19 Ventrica, Inc. Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart
US6651670B2 (en) 1998-02-13 2003-11-25 Ventrica, Inc. Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication
US6808498B2 (en) 1998-02-13 2004-10-26 Ventrica, Inc. Placing a guide member into a heart chamber through a coronary vessel and delivering devices for placing the coronary vessel in communication with the heart chamber
US20020144696A1 (en) 1998-02-13 2002-10-10 A. Adam Sharkawy Conduits for use in placing a target vessel in fluid communication with a source of blood
US5938697A (en) * 1998-03-04 1999-08-17 Scimed Life Systems, Inc. Stent having variable properties
US6176864B1 (en) * 1998-03-09 2001-01-23 Corvascular, Inc. Anastomosis device and method
US6029672A (en) * 1998-04-20 2000-02-29 Heartstent Corporation Transmyocardial implant procedure and tools
US6461320B1 (en) * 1998-08-12 2002-10-08 Cardica, Inc. Method and system for attaching a graft to a blood vessel
US6053942A (en) * 1998-08-18 2000-04-25 Heartstent Corporation Transmyocardial implant with coronary stent
US6196230B1 (en) * 1998-09-10 2001-03-06 Percardia, Inc. Stent delivery system and method of use
US6197050B1 (en) * 1998-09-14 2001-03-06 Heartstent Corporation Transmyocardial implant with compliance collar
US6190297B1 (en) * 1998-12-04 2001-02-20 Gerber Scientific Products, Inc. Apparatus for cutting and creasing sheet material
US7025773B2 (en) 1999-01-15 2006-04-11 Medtronic, Inc. Methods and devices for placing a conduit in fluid communication with a target vessel
US7578828B2 (en) * 1999-01-15 2009-08-25 Medtronic, Inc. Methods and devices for placing a conduit in fluid communication with a target vessel
AU2851000A (en) 1999-01-15 2000-08-01 Ventrica, Inc. Methods and devices for forming vascular anastomoses
WO2000069364A2 (en) * 1999-05-18 2000-11-23 Vascular Innovations, Inc. Implantable medical device such as an anastomosis device
US20030070683A1 (en) * 2000-03-04 2003-04-17 Deem Mark E. Methods and devices for use in performing pulmonary procedures

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055371A1 (en) * 1998-01-30 2003-03-20 Percardia, Inc. Left ventricular conduits to coronary arteries and methods for coronary bypass
US7294115B1 (en) * 1998-01-30 2007-11-13 Percardia, Inc. Methods of providing direct blood flow between a heart chamber and a coronary vessel
US20040077987A1 (en) * 1998-02-13 2004-04-22 Ventrica, Inc., Corporation Of Delaware Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication
US7137962B2 (en) 1998-02-13 2006-11-21 Medtronic, Inc. Devices and methods for use in performing transmyocardial coronary bypass
US7993356B2 (en) 1998-02-13 2011-08-09 Medtronic, Inc. Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication
US20030158573A1 (en) * 1998-02-13 2003-08-21 Ventrica, Inc Devices and methods for use in performing transmyocardial coronary bypass
US8512360B2 (en) 1998-02-13 2013-08-20 Medtronic, Inc. Conduits for use in placing a target vessel in fluid communication with source of blood
US7214234B2 (en) * 1998-02-13 2007-05-08 Medtronic, Inc. Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication
US6641610B2 (en) 1998-09-10 2003-11-04 Percardia, Inc. Valve designs for left ventricular conduits
US6694983B2 (en) 1998-09-10 2004-02-24 Percardia, Inc. Delivery methods for left ventricular conduit
US8216174B2 (en) 1998-09-10 2012-07-10 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US6610100B2 (en) 1998-09-10 2003-08-26 Percardia, Inc. Designs for left ventricular conduit
US7736327B2 (en) 1998-09-10 2010-06-15 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US7704222B2 (en) 1998-09-10 2010-04-27 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US8597226B2 (en) 1998-09-10 2013-12-03 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US6638237B1 (en) 1999-08-04 2003-10-28 Percardia, Inc. Left ventricular conduits and methods for delivery
US6582444B2 (en) 1999-08-04 2003-06-24 Percardia, Inc. Blood flow conduit delivery system and method of use
US6605113B2 (en) 1999-08-04 2003-08-12 Percardia Inc. Vascular graft bypass
WO2002030325A3 (en) * 2000-10-11 2002-08-22 Heartstent Corp Flexible transmyocardial implant
WO2002030326A3 (en) * 2000-10-11 2002-09-06 Heartstent Corp Transmyocardial implant with anchor element
WO2004073555A1 (en) * 2003-02-19 2004-09-02 Axel Haverich Methods and devices for improving cardiac output
US20050080476A1 (en) * 2003-10-09 2005-04-14 Gunderson Richard C. Medical device delivery system
US7967829B2 (en) 2003-10-09 2011-06-28 Boston Scientific Scimed, Inc. Medical device delivery system
US7799041B2 (en) 2004-03-23 2010-09-21 Correx, Inc. Apparatus and method for forming a hole in a hollow organ
US20070088375A1 (en) * 2004-03-23 2007-04-19 Correx, Inc. Apparatus and method for forming a hole in a hollow organ
US8226670B2 (en) 2004-03-23 2012-07-24 Correx, Inc. Apparatus and method for connecting a conduit to a hollow organ
US20110196408A1 (en) * 2004-03-23 2011-08-11 Correx, Inc. Apparatus and method for forming a hole in a hollow organ
US8679138B2 (en) 2004-03-23 2014-03-25 Correx, Inc. Apparatus and method for forming a hole in a hollow organ
US8277465B2 (en) 2004-12-15 2012-10-02 Correx, Inc. Apparatus and method for connecting a conduit to a hollow vessel
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US20070112422A1 (en) * 2005-11-16 2007-05-17 Mark Dehdashtian Transapical heart valve delivery system and method
US10314702B2 (en) 2005-11-16 2019-06-11 Edwards Lifesciences Corporation Transapical method of supplanting an implanted prosthetic heart valve
US8764820B2 (en) 2005-11-16 2014-07-01 Edwards Lifesciences Corporation Transapical heart valve delivery system and method
US11266500B2 (en) 2005-11-16 2022-03-08 Edwards Lifesciences Corporation Transapical heart valve delivery system
US9662207B2 (en) 2005-11-16 2017-05-30 Edwards Lifesciences Corporation Transapical method of delivering prosthetic heart valve
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11154398B2 (en) 2008-02-26 2021-10-26 JenaValve Technology. Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US20160082231A1 (en) * 2009-01-29 2016-03-24 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US9737697B2 (en) 2009-01-29 2017-08-22 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US10112036B2 (en) * 2009-01-29 2018-10-30 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US9381082B2 (en) 2011-04-22 2016-07-05 Edwards Lifesciences Corporation Devices, systems and methods for accurate positioning of a prosthetic valve
US10758353B2 (en) 2011-04-22 2020-09-01 Edwards Lifesciences Corporation Devices, systems and methods for accurate positioning of a prosthetic valve
US9999503B2 (en) 2011-04-22 2018-06-19 Edwards Lifesciences Corporation Devices, systems and methods for accurate positioning of a prosthetic valve
US11844693B2 (en) 2011-04-22 2023-12-19 Edwards Lifesciences Corporation Devices, systems and methods for accurate positioning of a prosthetic valve
US20130304111A1 (en) * 2012-05-11 2013-11-14 Michael Zhadkevich Anti-embolic device and method
US9655627B2 (en) * 2012-05-11 2017-05-23 Michael Zhadkevich Anti-embolic device and method
US10130374B2 (en) 2012-05-11 2018-11-20 Michael Zhadkevich Anti-embolic device and method
US11701126B2 (en) 2012-05-11 2023-07-18 Michael Zhadkevich Anti-embolic device and method
US11116517B2 (en) 2012-05-11 2021-09-14 Michael Zhadkevich Anti-embolic device and method
US11116515B2 (en) 2012-05-11 2021-09-14 Michael Zhadkevich Anti-embolic device and method
US11896485B2 (en) 2013-03-15 2024-02-13 Edwards Lifesciences Corporation System and method for transaortic delivery of a prosthetic heart valve
US10149757B2 (en) 2013-03-15 2018-12-11 Edwards Lifesciences Corporation System and method for transaortic delivery of a prosthetic heart valve
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US10596357B2 (en) 2014-01-15 2020-03-24 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US9737696B2 (en) 2014-01-15 2017-08-22 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US11278708B2 (en) 2014-01-15 2022-03-22 Tufts Medical Center, Inc. Endovascular cerebrospinal fluid shunt
US9808260B2 (en) 2014-05-04 2017-11-07 Zhadkevich Medical, Inc. Noninvasive protection from emboli
US10667825B2 (en) 2014-05-04 2020-06-02 Zhadkevich Medical, Inc. Noninvasive protection from emboli
US9687345B2 (en) 2014-05-29 2017-06-27 Edwards Lifesciences Cardiaq Llc Prosthesis, delivery device and methods of use
US11759212B2 (en) 2015-01-27 2023-09-19 Michael Zhadkevich Devices and techniques for vascular compression
US10258348B2 (en) 2015-01-27 2019-04-16 Michael Zhadkevich Devices and techniques for vascular compression
US11026697B2 (en) 2015-01-27 2021-06-08 Michael Zhadkevich Devices and techniques for vascular compression
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11103416B2 (en) 2015-09-28 2021-08-31 Michael Zhadkevich Device and method for simultaneous detection, monitoring and prevention of cerebral emboli
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
US10857017B2 (en) * 2017-07-14 2020-12-08 Bcm Co., Ltd. Stent insertion device for connecting human digestive organs
WO2021025905A1 (en) * 2019-08-06 2021-02-11 Edwards Lifesciences Corporation External cardiac bypass shunting

Also Published As

Publication number Publication date
CA2320956A1 (en) 1999-08-19
US20030158573A1 (en) 2003-08-21
AU755190B2 (en) 2002-12-05
JP2002502663A (en) 2002-01-29
AU2674699A (en) 1999-08-30
US7137962B2 (en) 2006-11-21
WO1999040868A1 (en) 1999-08-19
US20070055344A1 (en) 2007-03-08
EP1054641A1 (en) 2000-11-29

Similar Documents

Publication Publication Date Title
AU755190B2 (en) Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart
US20050043781A1 (en) Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart
US6808498B2 (en) Placing a guide member into a heart chamber through a coronary vessel and delivering devices for placing the coronary vessel in communication with the heart chamber
US7476234B2 (en) Transmyocardial revascularization system and method of use
US6447539B1 (en) Method and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion
EP1011523B1 (en) Apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion
US7849860B2 (en) Methods and apparatus for transmyocardial direct coronary revascularization
US20070010781A1 (en) Implantable aorto-coronary sinus shunt for myocardial revascularization
AU777443B2 (en) Methods and apparatus for direct coronary revascularization
AU761873B2 (en) Apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion
US20070010780A1 (en) Methods of implanting an aorto-coronary sinus shunt for myocardial revascularization
AU4352497A (en) Apparatus for treating ischemic heart disease by providing transvenous myocard ial perfusion
WO2007002616A2 (en) Implantable aorto-coronary sinus shunt for myocardial revascularization and method of usng the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDTRONIC, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VENTRICA, INC.;REEL/FRAME:015366/0710

Effective date: 20041029

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION